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1. INTRODUCTION 
 
 
1.1. GENERAL INTRODUCTION: (Dhanyakumar D. C.,2010; Bandari Suresh, 
2008 ,N.K. Jain, 2008; Kuchekar B.S. et al., 2003; Yie W. Chien, 2009) 
New drug-delivery technologies are often championed by contract 
manufacturing organizations. For new technologies that provide significant clinical as 
well as financial value, research and innovation in the contract manufacturing and 
pharmaceutical segments lead to the emergence of numerous competing versions of 
the technologies. Such a technology evolution has been evident for Orally 
Disintegrating Tablets . Designed to disintegrate rapidly on contact with saliva and 
enable oral administration without water or chewing, these formulations offer 
increased convenience and ease of administration with the potential to improve 
compliance, particularly in certain populations where swallowing conventional solid 
oral-dosage forms presents difficulties. 
 The Zydis (Catalent Pharma Solutions, Somerset, NJ) lyophilization 
technology provided the first approved Oral disintegrating tablets. (Claritin Reditabs, 
Schering Plough, Kenilworth, NJ) in the United States in 1996. 
Oral route of drug administration have wide acceptance up to 50 - 60% of total 
dosage forms. Solid dosage forms are popular because of 
1) Ease of administration 
2) Accurate dosage 
3) Self – medication 
4) Pain avoidance 
5) Patient compliance 
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The most popular solid dosage forms are being Tablets and Capsules; one 
important drawback of these dosage forms for some patients, is the difficulty to 
swallow. Drinking water plays an important role in the swallowing of oral dosage 
forms. Often times people experience inconvenience in swallowing conventional 
dosage forms such as tablets when water is not available, in the case of motion 
sickness (kinetosis) and sudden episodes of coughing during the common cold, 
allergic conditions and bronchitis. For these reasons, tablets that can rapidly dissolve 
or disintegrate in the oral cavity have attracted great deal of attention. 
Orodispersible Tablets are not only indicated for people who have swallowing 
difficulties, but also are ideal for active people.Orodispersible Tablets are also called 
as Mouth-dissolving tablets, Melt-in-mouth tablets, Fast dissolving tablets, Rapimelts, 
Porous tablets, Quick dissolving etc. 
 Orodispersible tablets are those when put on tongue, disintegrates 
instantaneously, releasing the drug, which dissolves or disperses in the saliva. The 
faster the drug into solution, quicker the absorption and onset of clinical effect. Some 
drugs are absorbed directly into the systemic circulation through the (oral) mucosa of 
mouth, pharynx and oesophagus as the saliva passes down into the stomach. In such 
cases, bioavailability of drug is significantly greater than those observed from 
conventional tablet dosage form. 
The advantages of mouth dissolving dosage forms are increasingly being 
recognized in both, industry and academics. Their growing importance was 
underlined recently when European Pharmacopoeia adopted the term “Orodispersible 
tablet” as a tablet that to be placed in the mouth where it disperses rapidly before 
swallowing. Latest era is an era of Novel Drug Delivery System. Formulation and  
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           Research is oriented towards increasing patient compliance, so the product 
development came on to screen. Product development has assured enormous 
significant in the modern pharmaceutical industry particularly as an impact of General 
Agreement on Trade and Tariff agreement and globalization as well as Patenting 
compulsions. Product development for well established bioactives (Drugs) is a highly 
rewarding proposition as this may extend the therapeutic life of such agents at a 
substantially low investment. Availability of several drugs as modified release dosage 
forms is one glaring example. For the last two decades, there has been enhanced 
demand for more patient compliance dosage forms. As a result, the industry sector for 
this area is approximately $14.20 billion in 1995 and is expected to grow to $60 
billion annually (from industry reports). Recent advances in Novel Drug Delivery 
System aim to enhance safety and efficacy of drug molecule by formulating a 
convenient dosage form for administration and to achieve the better patient 
compliance. 
Oral Drug Delivery has been the most extensively utilized route of 
administration for decades among all the routes that have been intended for the 
systemic deliverance of drugs by various pharmaceutical products of different dosage 
forms. The oral route achieved such fame due to its reward like self medication, ease 
of administration, non invasive, less expensive, patient compliance, versatility etc. 
  Drug delivery through the oral mucosa is a capable route, when one needs to 
attain a rapid onset of action or improved bioavailability for drugs with high first-pass 
metabolism .Thus, there is a growing interest in developing alternative dosage forms, 
i.e. orally fast disintegrating tablets, which allow a rapidly dissolving drug to absorb  
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directly into the systemic circulation through the oral mucosa. These kinds of dosage 
forms are also convenient for children, elderly patients with swallowing difficulties, 
and in the absence of potable liquids. However, in addition to formulation 
considerations, the properties of the active compound have to be appropriate in order 
to achieve drug delivery into systemic circulation after intraoral administration. The 
drug has to be soluble, fast dissolving and stable; and this might represent a hindrance 
for lipid soluble drugs. Due to the small volume of saliva in the oral cavity, the 
therapeutic dose of an intraoral drug must be relatively small. 
 
Dysphagia is common problem for children due to their under developed 
muscular and nervous systems. The uptake of traditional tablets in the cases like 
motion sickness, sudden episodes of allergic attacks or coughing or during 
unavailability of water is difficult. The different studies on the dysphagia showed that 
“26% of 1576 patients experienced difficulty in swallowing tablets and an estimated 
35% of general population, and an additional 30 - 40% of elderly institutionalized 
patients and 18 - 22% of all people in long term care facilitates” are sufferers from 
dysphagia. 
 
To accomplish above medical requirements, formulators have steadfast 
significant attempt for developing a novel type of dosage form for oral administration, 
known as the Immediate Release/ Fast Dissolving/ Oral Disintegrating Tablets and 
films. These dosage forms are most preferable for over the counter market. 
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1.2. ORAL DISINTEGRATING TABLETS (ODTs): (Suresh Bandari et al., 2008; 
Panigrahi D. et al., 2005; Shastry C.S. et al., 2004) 
          US Food and Drug Administration defined Orally Disintegrating Tablets as “a 
solid dosage form containing medicinal substances, which disintegrates rapidly, 
usually with in a matter of seconds, when placed upon tongue”. 
Recently European Pharmacopoeia also adopted the term ‘Orodispersible 
Tablet’ as a “Tablet that is to be placed in the mouth where it disperses readily and 
with in 3 minutes in mouth before swallowing". 
The US Food and Drug Administration 2008 publication of Guidance for 
Industry: Orally Disintegrating Tablets. Three main points stand out in the final 
guidance, those are as follows,                                                            
a. ODTs should have an in-vitro disintegration time of approximately 30 s or less 
(using United States Pharmacopeia Disintegration Test or equivalent). 
b. Generally, the ODT tablet weight should not exceed 500 mg, although the 
combined influence of tablet weight, size, and component solubility all factor into the 
acceptability of an ODT for both patients and regulators. 
The guidance serves to define the upper limits of the ODT category, but it does not 
supersede or replace the original regulatory definition mentioned. In other  words, 
disintegration within a matter of seconds remains the target for an  ODT. 
   The first developed Oral Disintegrating Tablet was developed in late 1970’s by 
the using of Zydis technology as an alternative to tablets, capsules, and syrups. 
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1.3. Anatomic and Physiologic Features of the Oral Cavity: (Anne Waugh, 
2006) 
The surface area of the oral mucosa is about 100 cm2. Three different types of 
oral mucosa are recognized: the mucosa, the lining mucosa, and the specialized 
mucosa. The masticatory mucosa, representing 25% of the total oral mucosa, is100–
200µm thick and covers the gingiva and the hard palate. It is tightly attached to 
underlying structures and subjected to abrasion and shear stress during mastication. 
The lining mucosa (60% of the total oral mucosa) is 500–800µm thick and covers the 
lips, cheeks, soft palate, lower surface of the tongue and the floor of the oral cavity. 
The specialized mucosa (15% of the total oral mucosa) is present on the dorsum of the 
tongue and is involved in taste. 
1.2.1. Buccal Epithelium 
The buccal epithelium is a non-keratinized stratified squamous epithelium, 
composed of multiple layers of cells that show different patterns of maturation 
between the deepest cells and the surface. The basal cells of the buccal epithelium are 
capable of division and maintain a constant epithelial population as cells move toward 
the surface. Tissue homeostasis requires differentiation followed by migration and 
desquamation of the superficial cells. The prickle cells (intermediate layer) 
accumulate lipids and cytokeratins of low molecular weight that do not aggregate to 
form filaments. An intracellular lipid portion is packaged in small organelles called 
membrane-coating granules or lamellar granules. Such granules migrate towards the 
apical surface of the cell, where their membrane fuses with the cell membrane and  
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their lipid content is extruded in the extracellular space. The buccal epithelium lacks 
tight junctions, which are common to intestinal and nasal mucosa, but is endowed 
with gap junctions, glydesmosomes and hemidesmosomes, which are loose 
intercellular links. The epithelium rests on the basal membrane, an irregular saliva 
continuous interface between the epithelium and the connective tissue. The basal 
membrane anchors the epithelium to the connective tissue and improves the barrier 
function of the epithelium, preventing large molecules from passing through the oral 
mucosa. 
          Although buccal absorption is not the specific goal of oral fast- dissolving 
tablets, this can occur when the drug is released in the oral cavity in contact with 
buccal mucosa. The drug transport mechanism through the buccal mucosa involves 
two major routes: 
• Transcellular (intracellular) 
• Paracellular (intercellular) 
          The transcellular route involves passage through the cellular membranes with 
a polar and a lipid domain, while the paracellular route essentially consists of passive 
diffusion through the extracellular lipid domain. It is generally recognized that the 
lipid matrix of the extracellular space plays an important role in the barrier function of 
the paracellular pathway, especially with compounds that are hydrophilic and have a 
high molecular weight, such as peptides. 
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1.3.1. Vascularization of the Oral Mucosa 
        Arterial, venous and lymphatic capillaries penetrate the multi- layered 
epithelium, infiltrating the connective tissue. The oral mucosa is primarily supplied by 
the external carotid artery, which serves the large buccal blood vessels. The floor of 
the mouth, the root of the tongue and the cheek mucosa are the most highly 
vascularized areas. Vascular drainage from the oral mucosa is primarily via the 
lingual, facial and retromandibular veins, which flow together into the internal jugular 
vein. This is the mechanism responsible for by passing first-pass hepatic metabolism. 
1.3.2. Salivary Flow 
       Saliva is the medium for disintegration or dissolution for drug formulations 
designed to disintegrate/dissolve in the oral cavity; for this reason, the properties of 
saliva are crucial to oral fast-dissolving tablets. The saliva is primarily secreted in the 
oral cavity by parotid, submandibular (submaxillary) and sublingual glands, and also 
by numerous minor glands. The main constituent of saliva is water (99.5% w/v). The 
remaining 0.5% w/v consists of dissolved compounds; in fact, saliva is a hypotonic 
solution (150–200 mOsm) compared with extracellular fluids (300 mOsm). The 
principal components of saliva are: inorganic electrolytes (0.2% w/v), including 
sodium, potassium, calcium, magnesium, bicarbonate and phosphates; gases (carbon 
dioxide, nitrogen, oxygen); nitrogen products such as urea and ammonia; ascorbic 
acid (vitamin C); creatinine; and mucins (high-molecular-weight glydesmosomes 
coproteins, which render the saliva viscous and adhesive). Saliva also contains amino  
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acids and proteins, digestive enzymes (salivary α-amylase [ptyalin], lipase, maltase, 
and lysozyme with antibacterial activity), proteolytic enzymes (moderate levels of 
esterase, carbohydrases and phosphatases), serum albumin and immunoglobulins. 
        Saliva has a weak buffering capacity and its normal pH value is slightly acid 
(pH 6–7); however, salivary flow pH can range from 5.3 (low flow) to 7.8 (peak 
flow). The accepted range of normal salivary flow is approximately 0.1–0.2 mL/min, 
increasing to 7 ml/min upon stimulation. Saliva wets the entire oral cavity and the 
resulting mucus layer ranges from 1 to 400µm in thickness, forming a physical barrier 
to drug permeation and a useful substrate for mucoadhesive drug delivery systems. 
1.4. SYNONYMS FOR ORAL DISINTEGRATING TABLETS: 
1) Oro Dispersible Tablets 
2) Porous Tablets 
3) Quickly Disintegrating Tablets 
4) Rapimelts 
5) Mouth Dissolving Tablets 
6) Fast Dissolving Tablets 
7) Fast Disintegrating Tablets 
8) Rapid Dissolving Tablets 
1.5. IDEAL CHARACTERISTICS OF ORAL DISINTEGRATING TABLETS: 
(Brahmeshwar Mishra et al., 2009)                         
a)Dosage form should be in a way that it should be taken without water. 
b)They should easily disintegrate or dissolve in oral cavity. 
c)The method of production need high drug loading. 
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d)They should produce pleasant mouth feel. 
e)They should not leave residue in the oral cavity after administration, as the drug 
passes into GIT. 
f)They should show low sensitivity against environmental circumstances i.e. moisture, 
temperature etc. 
g)Should allow the manufacture for using conventional processing. 
h)The packaging of the product should be readily adaptable to the conventional 
packaging equipment. 
i)The packaging of ODT formulation should be at low costs. 
j)The cost of the final product should be economical. 
1.6. ADVANTAGES  OF  ORAL  DISINTEGRATING  TABLET:  (Suresh Bandari        
et al., 2008, Brahmeshwar Mishra et al., 2009)       
    The motivating force in raising an Orally Disintegrating Tablets usage may include 
one or more of the following advantages, 
Patient Compliance: Allow patients to easily take the dosage form any time, any 
where, for systemic absorption. Medication as "bitter pill" has changed by excellent 
mouth feel property produced by use of flavors and sweeteners in ODTs. 
Patient Convenience: Enhance convenience to the patients in shipping and 
administrating these dosage forms particularly when travelling by designing them to 
taken without water. 
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Rapid Absorption and Onset of Action: Generate rapid absorption and faster onset 
of therapeutic efficacy mainly from the rapid disintegration or dissolving dosage 
forms. 
Avoidance of First-Pass Effect: Improve bioavailability owing to partial avoidance 
of first-pass metabolism resulting from pre gastric absorption. 
Elimination of Water/ Improved Stability: Provide an alternative to liquid dosage 
forms (i.e., syrups, solutions, dispersions) and thereby improve physical/ chemical                                          
integrity of the drug. 
Product Life-Cycle Management: Broaden the product life cycle by product 
differentiation by given alternative formulations of the conventional products. 
 
 
Figure 1.1 Advantages of Oral disintegrating tablets 
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        Figure 1.2    How Oral disintegrating tablets Differ from Conventional Tablets 
 
1.7.  LIMITATIONS OF ORAL DISINTEGRATING TABLETS:  (Suresh Bandari 
et al., 2008) 
 Certain drugs cannot be formulated as ODTs because of the following 
limitations: 
 The major disadvantage of ODTs is its mechanical strength. 
 Several ODTs are hygroscopic and cannot maintain physical integrity 
under normal condition from humidity which calls for specialized product 
packaging. 
ODTs are very porous and soft molded matrices or compressed into tablets with very 
low compression force, which makes the tablets friable and/or brittle which are 
difficult to handle, require specialized peel-off blister packaging.Bitter drugs or drugs  
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with a displeasing odor are complicated to formulate as ODTs. Special precautionary 
measures have to be taken before formulating such type of drugs. 
1.8. CHALLENGES TO DEVELOP ORAL DISINTEGRATING TABLETS: 
(Suresh Bandari et al., 2008) 
1.Achieve rapid disintegration of tablet. 
2.Avoid increase in tablet size. 
3.Possess sufficient mechanical strength. 
4.Leave minimum or no residue in mouth. 
5.Protection from moisture. 
6.Good package design. 
7.Compatible with taste masking technology. 
8.Not affected by drug properties. 
1.9. LIST OF DRUGS TO BE INCORPORATED IN ORAL DISINTEGRATING 
TABLETS:                             
Table 1.1 List of Drugs Suitable for ODTs 
CATEGORY OF DRUGS SOME EXAMPLES 
Analgesics Naproxen, Piroxicom, Sulindac, Ketoprofen 
Anthelmentics Albendazole, Ivermectin, Thiabendazole 
Anti- arrhythmic Agents Amiodarone HCl, Disopyramide, Flecainide 
acetate 
Anti-depressants Amoxapine, Ciclazindol, Maprotiline HCl 
Anti-diabetics Chlorpropamide, Glibenclamide, Gliclazide 
Anti-epileptics Beclamide, Carbamazepine, Clonazepam, Ethotoin 
Anti-hypertensive Agents Nifedipine, Nimodipine, Phenoxybenzamine HCl 
Anti-migraine Agents Methysergide, Pizotifen Maleate, Sumatriptan 
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1.10.TECHNICQUES OF ORAL DISINTEGRATING TABLETS FORMULATION:  
(Brahmeshwar Mishra et al., 2009) 
The fast-dissolving property of the ODTs is attributed to quick ingress of water 
into tablet matrix resulting in rapid disintegration. Hence, the basic approaches to 
develop ODTs include: 
a) Maximizing the porous structure of the tablet matrix. 
b) Incorporating the appropriate disintegrating agent/agents. 
Using highly water-soluble excipients in the formulation. 
Various manufacturing techniques for ODTs include: 
1. Lyophilization 
2. Moulding 
3. Direct Compression 
4. Cotton Candy Process 
5. Spray Drying 
6. Sublimation 
7. Mass Extrusion 
8. Nanonization 
1.10.1. Lyophilization: 
1.The mechanism or process behind the freeze-drying process includes 
following steps, 
3. The water is removed from the preparation by means of sublimation. 
4. After water removal the product undergoes to the freezing. 
Zydis, Quicksolv and Lyoc technologies used for the preparation of ODTs 
were come in to screen from this technology basis. Jaccard and Leyder improved  
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bioavailability of several drugs such as Spironolactone and Trolendomycin by 
utilizing this lyophilization technique. 
1.10.1.1. Zydis Technology: 
In present era of in fast-dissolving technology Zydis was the pioneer 
technology. The technology leads to formation of open matrix of water-soluble or 
water-dispersible carriers. This matrix will result in a structure with a density that is 
affected by the amount of active ingredient incorporated. The tridimensional structure 
leads to formation of solid foam with poor crystalline composition. When it places in 
the saliva it enters into the matrix through the pores leads to rapid disintegration. 
             The process of preparation  involves the following steps: 
Stage 1 - Preparation of an aqueous drug solution or suspension followed by filling 
the solution in the accurate dose in to the pre-formed blisters. 
Stage 2 - This step includes passing of filled blisters into a specially designed 
cryogenic freezers to undergo cryogenic freezing process to form the tablets with a 
porous matrix. This formation of the porous matrix leads to rapid disintegration. 
After the formation of the porous matrix tablets in the pre formed blisters, 
these units will move to the large-scale freeze dryers for sublimation process. In this 
step the majority of the remaining moisture is removed from the tablets. 
Stage 3 - Sealing the open blisters using a heat-seal process to ensure stability and 
protection of the product from varying environmental conditions. 
1.10.1.2. Lyoc: 
Lyoc is a technique that developed on the basis of the lyophilization. This 
process forms a porous and solid galenic form upon on lyophilization from an oil-in-
water emulsion of active ingredient with excipients placed directly in the blister  
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packets. This technique was applied to the preparation of ODTs of poorly soluble 
drugs. By this process high dose of drug can be loaded into the preparations. The 
disadvantage of this process is the formed product possesses poor mechanical 
strength. 
1.10.1.3. Quicksolv: 
Quicksolv is a porous solid form obtained by freezing an aqueous 
dispersion/solution of the drug containing matrix and then drying it by removing the 
water using excess of alcohol (solvent extraction). The maximum drug loading 
capacity for water insoluble and soluble drugs are 400 mg and 60 mg, respectively. 
The primary problems associated with water soluble drugs are the formation of 
eutectic mixtures resulting in freezing-point depression and the formation of a glassy 
solid on freezing which might collapse on drying due to loss of supporting structure 
during sublimation process. 
Advantages: 
1. Tablets produced by this technology have very low disintegration time. 
2. Tablets produced by this technology have great mouthfeel. 
Disadvantages: 
• This technology is an expensive and time consuming process. 
• The product obtained is poorly stable and fragile. 
• The conventional packaging is unsuitable for the products formed by this 
technique. 
1.10.2. Tablet Moulding: 
Tablet moulding is an old method of preparation of tablets. The different tablet 
moulding techniques in use are explained below. 
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1.10.2.1. Compression Moulding Process: 
 The tablets that produced by this process are less compact than compressed 
tablets with porous structure. The porous structure leads to the quicker dissolution 
rates. The technique follows the procedure as depicted below: 
 Moistening of powder blend with an organic solvent. 
 The coherent mass obtained is going to prepare into tablet by using mould 
plates. 
 The organic solvent is then removed by air drying process. 
1.10.2.2. Heat-Moulding Process: 
This process leads to formation of molten mass containing a dispersed drug. 
This process uses agar solution as a binder. The blister packaging is suitable for 
tablets produced by this process. The technique follows the procedure as depicted 
below: 
1. Preparation of a suspension contains drug, agar and sugar. 
2. Pouring the suspension into the blister packages. 
3. Solidifying the agar solution at 25°C to form a jelly. 
4. Drying the jelly at 30°C under vacuum to form tablet. 
1.10.2.3. Moulding by Vacuum Evaporation without Lyophilization: 
This process involves pouring of the drug excipient mixture (in the form of a 
slurry or paste) into a mould of desired dimension, freezing the mixture to form a 
solidified matrix and finally subjecting it to vacuum drying at a temperature within 
the range of its collapse temperature and equilibrium freezing temperature. 
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Advantages: 
 Improving taste and mouthfeel. 
 rapid disintegration 
Disadvantages: 
Poor mechanical strength, they may undergo erosion and breaking during 
handling. 
1.10.3. Direct Compression (DC): 
Direct compression is a well known and simplest manufacturing technique for 
ODTs. It is most cost effective technique for the manufacturing of tablets. It is mostly 
using method because of its exclusive features like adoptability of the ordinary 
conventional manufacturing and packaging machinery. 
1.10.3.1. Disintegrants: 
In many ODT products based on direct compression process, the disintegrants 
mainly affect the rate of disintegration and hence dissolution which is further 
enhanced in the presence of water soluble excipients and effervescent agents. Tablet 
disintegration time can be optimized by focusing on the disintegrant concentration. 
Below a critical disintegrant concentration, tablet disintegration time becomes 
inversely proportional to disintegrant concentration. However, above the critical 
concentration level of disintegrant, disintegration time remains approximately 
constant or the decrease is insignificant. 
1.10.3.1.1. Flashtab: 
Flashtab is a technology designed based on the direct compression method. 
This technology produces coated crystals of drug and micro granules along with the 
disintegrants. 
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1.10.3.2. Effervescent Agents:       
 The formation of CO2 from the effervescence agents made basis for utilization 
of this in the preparation of ODTs. The saliva in mouth causes the production of 
effervescence, which causes the tablet disintegration in mouth. Orasolv and Durasolv 
are the patented technologies prepared on this basis. 
1.10.3.2.1. Orasolv:                                                           
Orasolv is the first-generation technology developed on the basis of 
effervescence to produce ODTs. The technique follows the procedure as depicted 
below: 
      1.Formulation of  microparticles containing the drug with suitable       
         polymer along with other excipients . 
 2.The formulated particles were dried at 50°C for one hour. 
     3.The dried particles sieved through 8 - mesh and dried for 1hour at 60°C. 
 4.Compression of dried microparticles into tablets at 1.0–2.0 kilo pound 
hardness. 
1.10.3.2.2. Durasolv: 
Durasolv, a second generation technology developed based on effervescence 
approach to produce ODTs. The tablets produced by this technique can give much 
faster release and cost effective. The product is suitable for the traditional blisterpacks 
or vials. The demerits of this technology are low drug loading capacity and high 
compaction pressure. 
1.10.3.3. Sugar-Based Excipients: 
This is another approach to manufacture ODTs by Direct compression 
technique. In this approach the sugar-based excipients (e.g., dextrose, fructose,  
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isomalt, lactitol, maltitol, maltose, mannitol, sorbitol, starch hydrolysate, polydextrose 
and xylitol) were used to enhance the solubility and sweetness of the product. Thus 
the product formed will produce a good mouthfeel effect. Two types of saccharides 
are using in this technique those are as follows: 
1)Type I saccharides (e.g., lactose and mannitol) exhibits low mouldability but     high 
dissolution rate. 
2)Type II saccharides (e.g., maltose and maltitol) exhibits high mouldability but low 
dissolution rate. 
The mouldability of Type I saccharide can be enhanced by granulating it with a Type 
II saccharide solution. 
1.10.3.3.1. Wowtab: 
WOWTAB is a technology, which involves the use of fluidized bed 
granulation for the surface treatment of Type I saccharide with Type II saccharide. 
The WOWTAB formulation products are more stable than the Zydis or Orasolv 
products and suitable for both conventional bottle and blister packaging. 
1.10.3.3.2. Ziplet: 
Recently, the Ziplet technology is a newer technology developed recently, 
which can be used for hydrophobic drugs. The incorporation of water-insoluble 
inorganic excipient with one or more effective disintegrants gives an excellent 
disintegration. 
1.10.4. Cotton Candy Process or Flashdose: 
The FLASHDOSE is type of ODT manufactured by means of Shearform™ 
technology in association with Ceform TI™ technology to abolish the bitter taste of 
the medicament. 
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1.10.5. Spray-Drying: 
For the making of ODTs the spray drying technique was used first by Allen. 
The formulation that he developed consisting of gelatin as a supporting agent (for 
matrix of tablet). Mannitol used as a bulking agent and sodium starch 
glycolate/croscarmellose as a disintegrant. The suspension of these above said 
excipients was spray-dried to yield a porous powder. Then the porous powder 
was compressed into tablets. 
1.10.6. Sublimation: 
 It is also a well acknowledged method for the preparation of ODTs. The ODTs 
produced by this method is very high porous. A porous matrix will form by 
sublimation of the volatile ingredients in the tablet.The volatile substances used in this 
process are ammonium bicarbonate, ammonium carbonate, benzoic acid, camphor, 
hexamethylene tetramine, naphthalene, phthalic anhydride, urea and urethane. 
Cyclohexane and benzene were used as solvents. 
The process involves formation of a tablet with the blend of volatile 
substances and subsequent removal of the solvent by sublimation. While sublimation 
the removed place of the volatile substance will stay unfilled and provide extremely 
porous structure which, leads to quick entry of saliva in the mouth and rapid 
disintegration of tablet. The tablets prepared by this technique are mechanically less 
stable.          
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Figure:1.3: Sublimation technique 
1.10.7. Mass-Extrusion: 
The mass-extrusion technique is used for the preparation of ODTs mainly of bitter 
drugs due to its high taste masking property. The process is as follows: 
The preparation of a soft blend of active constituent by incorporation of mixture of 
water soluble polyethylene glycol and methanol.Expulsion of above softened mass 
through an extruder or syringe to get a cylindrical shaped extrude.Formation of tablets 
by cutting extrude into even segments using heated blade 
1.10.8. Nanonization: 
A recently developed Nanomelt technology involves reduction in the particle size of 
drug to nanosize by milling the drug using a proprietary wet-milling technique.  
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The processes are depicted as flowcharts in Figure 1.4 A and 1.4 B. 
 
Figure 1.4  Processes Involved in the Preparation of    ODTs   
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Table 1.2 List of Patented Technologies Based Branded Products 
Patented 
Technology 
Basis of 
Technology 
Technology 
Developed by 
Company 
Active Ingredient 
(Brand Names) 
Zydis Lyophilization R.P.Scherer Inc. 
Loratidine (Claritin Reditab 
and Dimetab) 
Quicksolv Lyophilization Janssen 
pharmaceutics 
Cisapride monohydrate 
(Propulsid (Quicksolv) 
Lyoc Lyophilization Farmalyoc 
Phloroglucinol Hydrate 
(Spasfon Lyoc) 
Flashtab 
Direct 
Compression 
Ethypharm 
Ibuprofen 
(Nurofen Flashtab) 
Orasolv 
Direct 
Compression 
Cima Labs Inc. 
Paracetamol (Tempra 
Quicklets), Zolmitriptan 
(Zolmig Repimelt) 
Durasolv 
Direct 
Compression 
Cima Labs Inc. 
Hyoscyamine Sulfate 
(NuLev) Zolmitriptan 
(Zolmig ZMT) 
Wowtab 
Direct 
compression 
Yamanouchi Pharma 
Tech. Famotidine (Gaster D) 
Ziplets 
Direct 
compression 
Eurand International 
Ibuprofen (Cibalgina 
DueFast) 
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1.11.TABLET DISINTEGRATION AND DISINTEGRANTS:(Debjit Bhowmik et al., 
2009) 
         Disintegration is the process of breaking up to smaller particles. Tablet 
disintegration is “the process of breaking up of tablet to the fine particles/ smaller 
pieces”. A disintegrant helps the tablet to break up into smaller pieces upon contact 
with aqueous solution. 
         Disintegration of ODTs starts when a small amount of saliva contacts the dosage 
form (wetting) and penetrates the tablet matrix. Disintegrants or superdisintegrants 
with efficient disintegrating properties can be used in the formulation of ODTs. They 
are generally added at a level of 1 – 10% (w/w %). 
        The general mechanism of disintegration is shown in Figure 1.5. 
1.11.1. Conceptual Diagram of Tablet Disintegration: 
 
Figure 1.5 Mechanism of ODTs Disintegration 
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 There are four major mechanisms for tablets disintegration as follows, 
1.11.1.1. Swelling: 
It is the general mechanism of action for tablet disintegration. The porosity is 
main parameter to exert this action. The mechanism of disintegration is depicted in 
the Figure 1.6. It is worthwhile to note that if the packing fraction is very high, fluid is 
unable to penetrate in the tablet and disintegration is again slows down. 
 
Figure 1.6 Disintegration Due to swelling 
1.11.1.2. Porosity and Capillary Action (Wicking): 
The mechanism of wicking is when a tablet contact with the medium the 
medium is pulled in to the tablet pores and causes to break the particulate forces 
inside that which intern leads to disintegration. It is given in Figure 1.7. 
 
Figure 1.7 Disintegration Due to Wicking 
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1.11.1.3. Due to Disintegrating Particle/Particle Repulsive Forces:        
 It is followed by the ‘non-swellable’ disintegrants. The electric repulsive 
forces between particles lead to disintegration of ODTs. It is shown in Figure 1.8. 
 
Figure 1.8 Disintegration Due to Repulsion 
1.11.1.4. Due to Deformation: 
As we know the deformation occurs in the tablet compression this deformation 
may fail when contact with medium. The second deformation that occurs in the above 
process or gaining of the original nature of components called as deformation here. 
The deformation process is given in Figure 1.9. 
 
 
Figure 1.9 Disintegration Due to Deformation 
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1.11.2. Commonly used Superdisintegrants:    (Debjit Bhowmik et al., 2009) 
 Table 1.3 List of Commonly Employed Superdisintegrants in ODTs 
 
 
Superdisintegrants Nature Particle Size Mechanism 
Crospovidone 
Cross linked homo 
polymer of N-vinyl-
2-pyrrolidone 
Particle size- 
100µm 
Both swelling and 
wicking 
Croscarmellose 
sodium 
Cross-linked form of 
sodium CMC 
Particle size 200 
mesh Swelling 
Sodium starch 
Glycolate 
Cross linked low 
substituted carboxy 
methyl ether of poly-
glucopyranose 
Particle size 140 
mesh 
Water uptake followed 
by rapid and enormous 
swelling 
Acrylic acid 
derivatives 
Poly(acrylic acid) 
super porous hydro 
gel 
Insoluble in 
organic solvents, 
disperses in cold 
water 
Wicking action 
Effervescent mixture 
Citric acid, tartaric 
acid, sodium 
bicarbonate 
Crystalline nature Effervescence 
Sodium alginate Sodium salt of alginic 
acid 
Slowly soluble in 
water, hygroscopic Swelling 
NS-300 Carboxy methyl 
cellulose (CMC) 
Particle size 106 
µm Wicking type 
ECG-505 Calcium salt of CMC Particle size 106µm Swelling type 
L-HPC Low hydroxyl propyl 
cellulose 
Particle size 
106µm 
Both swelling and 
wicking 
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Table 1.4 List of ODT Products Available in the Indian Market 
 
Brand Name Active Ingredient Company 
Domray MD Domperidone Ray remedies 
Veirid MD Domperidone Shreyam healthcare 
Omidon MD Domperidone Olcare labs 
Zotacet MD Cetrizine HCl Zota pharma 
Olanex Instab Olanzepine Ranbaxy 
Romilast Montelukast Ranbaxy 
Torrox MT Rofecoxib Torrent 
Dolib MD Rofecoxib Panacea 
Orthoref MD Rofecoxib Biochem 
Zofex-25 MD Rofecoxib Zota pharma 
Nexus MD Nimesulide Lexus 
Nimex MD Nimesulide Mexon healthcare 
Nisure-MD Nimesulide Suzen pharma 
Olnim- MD Nimuesulide Olcare Lab 
 
Table 1.5 List of ODT Products Available in the International Market   
Brand Name Active Ingredient Company 
Felden fast melt Piroxicam Pfizer Inc., USA. 
Claritin redi Tab Loratidine ScheringploughCorp,USA. 
Zyprexia Olanzapine Ei lily, USA. 
Zofran ODT Ondansetron Glaxo Wellcome, UK. 
Pepcid RPD Famotidine Merck and Co., USA. 
Zoming- ZMT Zolmitriptan Astra Zeneca, USA. 
Febrectol Paracetamol Prographarm, France. 
Nimulid MDT Nimusilide Pancea Biotech, India. 
Risperdal M Tab Risperidone Janseen pharmaceuticals 
Tempra Quicklets Paracetamol Cima Labs, France. 
Zolming Rapimelt Zolmitriptan Cima Labs, France. 
Kemstro Baclofen Schwarz Pharma 
Benadryl Fastmelt Diphenhydramine Pfizer Inc., USA. 
Gaaster D Famotidine Yamanouchi. 
Nasea OD Ramosetron Yamanouchi. 
 
1.12. Salient Features of Mouth Dissolving Drug Delivery System 
1) Ease of administration to pediatric, geriatric and psychiatric patients who 
refuse to swallow a tablet. 
2) Convenient for administration and accurate dosing as compared to liquids. 
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3) No need of water to swallow the dosage form, which is highly convenient 
feature for patients who are depressed. 
4) Good mouth feel property of MDDDS helps to change the basic 
impression of medication as ‘Bitter Pill’ particularly for pediatric patients. 
5) As ODTs are unit solid dosage forms, they provide good stability, accurate 
dosing, easy manufacturing, small packaging size, and easy to handle by 
patients. 
6) Rapid dissolution and absorption of drug, which may produce rapid onset 
of action. 
7) Some drugs are absorbed from the mouth, pharynx and oesophagus as the 
saliva passes down into the stomach, which enhances bioavailability of 
drugs by avoiding hepatic metabolism. 
8) Ability to provide advantage of liquid medication in the form of solid 
preparation. 
1.13. Strategies of Taste Masking:  (Roop K.Khar, 2001) 
a)Taste is one of the most important parameters governing patient compliance. 
Undesirable taste is one of several important formulation problems that are 
encountered with certain drugs. Four fundamental sensations of taste have been 
described: 
b)Sweet and salty, mainly at the tip. 
c)Sour, at the sides. 
d)Bitter, at the back. 
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e)Taste masking is defined as a perceived reduction of an undesirable taste that would 
otherwise exist. 
 Various techniques available for masking bitter taste of drugs include taste 
masking with ingredients such as flavors, sweeteners, and amino acids; taste masking 
by polymer coating; taste masking by conventional granulation; taste masking with 
ion-exchange resins; taste masking by spray congealing with lipids; taste masking by 
formation of inclusion complexes with cyclodextrins; taste masking by the freeze-
drying process; taste masking by making multiple emulsions; and taste masking with 
gelatin, gelatinized starch, liposomes, lecithins or lecithin-like substances, surfactants, 
salts, or polymeric membranes. 
1.13.1. Taste Masking with Flavors, Sweeteners, and Amino Acids 
         This technique is the foremost and the simplest approach for taste masking, 
especially in the case of pediatric formulations, chewable tablets, and liquid 
formulations. But this approach is not very successful for highly bitter and highly 
water soluble drugs. Artificial sweeteners and flavors are generally being used along 
with other taste-masking techniques to improve the efficiency of these techniques. 
Aspartame is used as a prominent sweetener in providing bitterness reduction. A very 
small concentration (0.8%) is effective in reducing the bitterness of 25% 
acetaminophen. Starch, lactose, and mannitol have also exhibited taste-masking 
properties of caffeine. Anticholesterolemic saponin-containing foods, beverages, and 
pharmaceuticals are supplemented with amino acids (such as glycine and alanine) and 
flavors for bitterness control. 
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1.13.2. Taste Masking with Lipophilic Vehicles: 
Lipids: 
  Oils, surfactants, polyalcohols, and lipids effectively increase the viscosity in 
the mouth and coat the taste buds, and therefore they are potential taste masking 
agents. Guaifenesin has improved taste when mixed with carnauba wax and 
magnesium aluminium silicate and then melt-granulated. 
Lecithin and Lecithin-like Substances: 
  Formulations with a large excess of lecithin or lecithin-like substances are 
claimed to control bitter taste in pharmaceuticals. Magnesium aluminum silicate with 
soybean lecithin is used to mask the unpleasant taste of talampicillin Hydrochloride. 
The drug is dissolved in or dispersed into an organic solvent such as chloroform. 
Lecithin is added to the solution or dispersion of the drug with stirring to give a blend. 
The blend is mixed with powdery excipients (e.g., magnesium aluminate metasilicate, 
synthetic aluminum silicate, lactose, mannitol, etc.), dried and granulated to give a 
taste-masked composition. 
1.13.3. Taste Masking by Coating with Hydrophilic Vehicles: 
 This is the simplest and most feasible option to achieve taste masking. The 
coating acts as a physical barrier to the drug particles, thereby minimizing interaction 
between the drug and taste buds. Coating of chewable tablets provides excellent taste 
masking while still providing acceptable bioavailability. A specialized technique, i.e.,  
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micro emulsion technology, has been used for taste masking of powders, chewable 
tablets, and liquid suspensions. 
1.13.4. Carbohydrates (Cellulose): 
 The taste of orally administered drugs can be masked by coating the drug with 
carbohydrates. Bitter solid drugs such as pinaverium bromide, a spasmolytic, has no 
bitter taste when formulated in an organoleptically acceptable manner by polymer 
coating with a mixture of cellulose or shellac and a second film forming polymer 
soluble at pH less than 5. 
1.13.5. Taste Masking by Inclusion Complexation: 
 In inclusion complex formation, the drug molecule fits into the cavity of a 
complexing agent, i.e., the host molecule, forming a stable complex. The complexing 
agent is capable of masking the bitter taste of drug by either decreasing its oral 
solubility on ingestion or decreasing the amount of drug particles exposed to taste 
buds, thereby reducing the perception of bitter taste. This method is most suitable 
only for low dose drugs. Vander Waals forces are mainly involved in inclusion 
complexes. The suppression of bitter taste by cyclodextrin was in increasing order of 
alpha, gamma, and beta cyclodextrin. β-cyclodextrin is the most widely used 
complexing agent for inclusion type complexes. It is a sweet, nontoxic, cyclic 
oligosaccharide obtained from starch. 
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1.13.6. Solid Dispersion System: 
 Solid dispersion have been defined as dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state prepared by melting (fusion) 
solvent or melting solvent method. Solid dispersion is also called as co precipitates for 
those preparation obtained by solvent method. Solid dispersion of drug with the help 
of polymers, sugar, or other suitable agents, is very useful for taste masking. The 
bitter taste of dimenhydrinate can be masked by preparing the solid dispersion of the 
drug with polyvinyl acetate phthalate. Solid dispersions using insoluble matrices or 
bland matrices may be used to mask the bitter taste of drugs. Also using them as 
absorbents on various carriers may increase the stability of certain drugs. 
1.13.7. Prodrugs:    
 A prodrug is a chemically modified inert drug precursor, which upon 
biotransformation liberates the pharmacologically active parent drug. The 
alkyloxyalkyl carbonates of the clarithromycin 2’ position have remarkably alleviated 
bitterness and improved bioavailability when administered orally.Tasteless/bitter le ss 
prodrugs of opioid analgesics and antagonists were formulated for improved buccal 
delivery. Tasteless prodrugs of nalbuphine Hydrochloride, naltrexone, naloxone, 
oxymorphone Hydrochloride, butorphanonol, and levallorphan were synthesized for 
buccal administration to improve bioavailability relative to that of oral dosing without 
the characteristic bitter taste. 
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1.13.8. Ion Exchange Resin: 
 Another popular approach in the development of taste masking is based on ion 
exchange resin. Ion exchange resins are solid and suitably insoluble high molecular 
weight polyelectrolytes that can exchange their mobile ions of equal charge with the 
surrounding medium. The resulting ion exchange is reversible and stiochiometric with 
the displacement of one ionic species by another. Ion exchange resins can be 
classified into four major groups: 
a)Strong acid cation-exchange resin. 
b) Weak acid cation-exchange resin. 
c) Strong base anion-exchange resin. 
d) Weak base anion-exchange resin. 
e) Strong acid cation resins (sulfonated styrene di vinyl bezene copolymer product) 
function throughout the entire pH range and can be used for masking the taste of basic 
drugs. Weak acid cation exchange resins function at pH values above 6.0. Similarly, 
strong base anion-exchange resins function throughout the entire pH range and can be 
used for masking the taste of acidic drugs, while the weak base anion exchange resins 
function well below pH 7.0 Synthetic ion exchange resin have been used in pharmacy 
and medicine for taste masking or controlled release of drug as early as 1950. 
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1.13.9. Miscellaneous Taste-Masking Approaches: 
a)By Effervescent Agent: 
  Effervescent agents have been shown to be useful and advantageous for oral 
administration of drugs and have also been employed for use as taste-masking agents 
for dosage forms that are not dissolved in water prior to administration. A chewing 
gum composition of bitter medicament(s) was formulated to supply the 
medicament(s) to the oral cavity for local application or for buccal absorption. It 
comprises a chewing gum base, an orally administrable medicament, a taste masking 
generator of carbon dioxide, and optionally a taste bud desensitizing composition 
(e.g., oral anesthetics such as benzocaine and spilanthol) and other nonactive 
materials, such as sweeteners, flavoring components, and fillers. Recently, 
effervescent tablets of fentanyl and prochlorperazine were developed to supply these 
drugs to the oral cavity for buccal, sublingual, and gingival absorption. 
b)Salt Preparation: 
  Adding alkaline metal bicarbonate such as sodium bicarbonate masks the 
unpleasant taste of water-soluble ibuprofen salts in aqueous solution. The bitter taste 
of caffeine may be masked by formulating it as a carbonated oral solid preparation 
using sodium bicarbonate, ascorbic acid, citric acid, and tartaric acid. Magnesium 
aspirin tablets are rendered tasteless by preparing magnesium salts of aspirin. 
Penicillin prepared as N, N’-dibenzylethylene-diamine diacetate salts or N, N’-bis 
(deyhdroabiety) ethylenediamine salts is tasteless. Bitterness-reduced antitussive and 
expectorant compositions (tablets) of dihydrocodeine phosphate, DL-methylephedrine  
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Hydrochloride, and D-chlorpheniramine maleate contain magnesium salts, 
sweeteners, starch, and cellulose. 
c)Freeze Drying Process: 
 This method is used to develop fast-dissolving oral technologies such as Zydis 
and Lyoc technology. Zydis is a tablet-shaped dosage form that spontaneously 
disintegrates in the mouth in seconds. This is due to the high porosity produced by the 
freeze drying process. The Zydis process requires the active ingredient to be dissolved 
or suspended in an aqueous solution of water soluble structure formers. The resultant 
mixture is then poured into the preformed blister pockets of a laminate film and freeze 
dried. The two most commonly used structural excipients are gelatin and mannitol, 
although other suitable excipients can be used (e.g., starches, gums, etc.). This process 
is ideally suited to low solubility drugs as these are more readily freeze dried. Taste is 
very important for this type of dosage form and it is possible to produce palatable 
formulations by using artificial sweeteners (e.g., aspartame) and conventional flavors. 
Various drugs have been taste-masked by Zydis technology. These are lorazepam 
(Wyeth), piroxicam (Pfizer), loperamide (Janssen), ondansetron (Glaxo Wellcome), 
rizatriptan (Merck), loratadine (Schering Plough), olanzapine (Eli Lilly), selegiline 
(Elan), scopolamine/ chlorpheniramine (Taisho), etc. 
1.14. TASTE ASSESSMENT: 
  Taste assessment one of the important quality control parameters for 
evaluation of taste masked formulation .Drug or formulation can be assessed using in 
vivo and in vitro method of taste evaluation parameters. 
 
 TASTE  MASKED  POROUS TABLETS OF LOSARTAN POTASSIUM                                              INTRODUCTION  
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR  38 
a)In vitro approaches taste assessment: 
b)In vitro drug release studies: 
 Pharmacopoeial release studies have been modified by altering the chemical 
composition of the dissolution media (e.g. artificial saliva) and reducing the size of 
the basket screen size (screen size< 0.381 mm square opening) to prevent particles 
forms escaping. Taste masking is achieved when, in the early time points from 0-5 
minutes the drugs substances in the dissolution medium is either not detected or 
amount is below the threshold for identifying its taste. Drug can be analyzed either 
spectrophotometrically or using HPLC. Of these HPLC is generally preferred 
especially when testing is performed in the presences of UV-absorbing component, 
such as flavorings and sweetener. A novel invivo buckle dissolution testing apparatus 
and method for the assessment of taste masking in oral dosages forms have recently 
been invented. The apparatus consists of a single, stirred, flow-through filtration cell 
including a dip tube designed to remove fine solid particles. Simulated saliva is used 
as the dissolution medium. The filtrated solution is removed from the apparatus 
continuously and used to analyze the dissolve drug. 
1) Voltramettric electronic tongue: 
         The Voltramettric electronic tongue developed by s-*sense consistent of four 
working metal electrode made of gold, platinum, iridium and rhodium an Ag/AgCl 
references and a stainless steel counter electrode. A relay box enables the working 
electrode to be connected consecutively, to form four standards three-electrode 
configurations. The potentially pulse are applied by a potentiostat which is controlled  
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by a personnel computer. The PC used to set and control the pulse, measure and store 
current response, and to operate the relay box. 
2)Electronic tongue: 
         The electronic tongue initially developed by the University of Taxes consists of 
a light sources, a sensors array and detector. The light sources shines onto chemically 
adapted polymer beads arranged on a small silicon wafer, which is known as a sensors 
chip the beads change is color on the basis of the presences and quality of specific 
chemical. The change is color is capture by a digital camera and the resulting signal 
converted into data using video capture board and a computer. 
c) In vivo approaches for taste assessment 
In vivo studies, stimuli are applied on to the tongue of either human or animals. 
1) Human taste panel studies: 
         Human taste panel studies evaluated tastant (food, chemical, drug and so on) by 
estimating the gustatory sensation response in healthy human volunteers within well-
controlled process. Such studies are there for also known as physiological evaluation, 
gustatory sensation testes or taste trials. They are sensitively measured of taste and are 
spastically designed to minimize bias and response within and between human 
volunteers. Well-established methodology for performing sensory analysis can be 
broadly divided into five types, namely discrimination taste. Scaling taste, experts 
testers, affective taste and descriptive methods and have been excellency discussed. 
Volunteers asses the taste quality and intensity of standard are taste stimuli on  
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different adjective scales including various properties of the sample, such as overall 
intensity, sweet, odor, bitter, metallic, cooling, hot, spicy, anesthetic, astringent etc. 
Each adjective can be rated as intensity rated on the scale zero to four a perhaps even 
up to nine points on the provided score rates. 
2) Animal preference testes: 
 Bottle performance and condition taste aversion taste are used for taste for 
determining taste preference and concentration-response properties of tastant by 
animal 3 and 4 rats, mice, cats and dogs can be used for the potentiometrically e-
tongue, incorporating and array of artificial lipid-polymer membranes as a fingerprint 
devices, has been developed as a promising tool for use in the quality control of 
phytomedicines. The miniaturization of taste sensors is particularly interest for the 
food and pharmaceutical industries. A portable low-cost sensing system has been 
made that interfaces to a Voltramettric electronic tongue sensors. Screen-printing 
technologies have been used to develop disposable taste sensors. 
1.14. Patient Counseling in effective use of Fast Dissolving Tablets 
ODT developed offers significant advantages for various groups of patients, 
but the majority of patients receiving ODT have little understanding of this novel 
dosage form. Patients receiving ODT may be surprised when tablets begin to 
disintegrate/dissolve in mouth. As pharmacists are ideal persons to know about the 
recent technologies, thus have opportunity to educate the patient for effective 
treatment. Counseling of patients about this dosage form can avoid any confusion and  
misunderstanding in taking ODT. Patient information that needs to be provided 
includes 
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1. Storage of this dosage form as some of ODT developed may not have sufficient 
mechanical strength, which needs to be handled carefully. 
2.  Patients with Siogren's syndrome or dryness of mouth or who take anti 
cholinergic drugs may not be suitable candidates for administering ODT. Although 
no water is required to allow drug to disperse quickly and efficiently but decreased 
volume of saliva may slow the rate of disintegration/dissolution and may reduce 
the bioavailability of the product 
3. Patients need to be clearly told about the difference between effervescent and 
ODT. Some of technologies use effervescence, which experience a pleasing 
tingling effect on the tongue. 
4.  Although chewable tablets are available in market and patient need to be 
counseled about differences between chewable and ODT tablets. This ODT can be 
used easily in children who have lost their primary teeth and in geriatric patients 
who have lost their teeth permanently. 
5.  Patients may mistake fast-dissolving/disintegrating for effervescent tablets. 
Pharmacists may wish to stress the difference between the use of quick-dissolving 
and effervescent tablets. The Cima technologies, OraSolv and DuraSolv, use slight 
effervescence. Patients may experience a pleasant tingling on the tongue with 
OraSolv and DuraSolv. 
6.   With the pharmacists counseling, intervention and assistance about ODT, all 
patients receiving this novel dosage form could be more properly and effectively 
treated with greater convience.                                                                                      
 
  
 
 
NEED  AND 
OBJECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
TASTE  MASKED   POROUS  TABLETS OF LOSARTAN POTASSIUM                    NEED AND OBJECTIVES 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR  42 
 
 
2.NEED AND OBJECTIVES 
The present study was expected to develop Losartan potassium taste masked 
porous tablets by sublimation technique by using sublimating agents.      
 In order to assist patients during travelling (where there will be unavailability 
of water), and to the patients who feel difficulty in swallowing, there is a necessity for 
the development of these oral disintegrating drug delivery systems. Losartan 
pottasium was rapidly absorbed and had less bioavailability, thereby an increased in 
the bio- availability of the drug may be observed if given as Losartan pottasium 
porous tablets. 
 The dosage form was designed in such a way that they disintegrate in patient’s 
mouth upon on contact with saliva within seconds without aid of water. The drug then 
enters in to stomach as fine particles which may get rapidly absorbed and the pre 
gastric absorption leads to the faster onset of action. The investigation was undertaken 
with a view to formulate porous tablets and to get the quick onset of action in 
treatment of a suddenly arising hypertension. Use of sensory approach to enhance 
patient compliance and to evaluate these formulations by in-vitro methods and to 
select the best formulation among them in all dosage forms. 
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3.PLAN    OF    WORK 
The study was planned to carry out as follows, 
9) LITERATURE SURVEY 
10) FORMULATION AND DESIGN FOR POROUS TABLETS 
11) PROCUREMENT OF DRUG AND EXCIPIENTS 
12) EXPERIMENTAL WORK 
PRELIMINARY STUDIES 
I) Identification of drug 
                     a.By FTIR Spectroscopy 
                     b.By Melting point 
Physico-Chemical parameters 
a. Organoleptic properties 
b.Solubility profile 
 II) Analytical methods 
a) Determination  of λmax 
b) Development  of standard curve of drug in the determined λmax 
c) Determination of percentage purity of drug 
 III) Determination of compatibility of drug with excipients 
o By FTIR Spectroscopy 
o By DSC Thermal Analysis 
IV) Preparation and characterization of powder blend of porous  tablets 
 Angle of Repose 
 Loose Bulk Density 
 Tapped Bulk Density 
TASTE  MASKED  POROUS TABLETS  OF  LOSARTAN  POTASSIUM                         PLAN OF WORK 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR 44 
 
 Hausner’s Ratio 
 Carr’s Compressibility Index 
V) Formulation 
VI) Evaluation 
7. General Appearance 
8. Thickness and Diameter 
9. Weight Variation 
10. Hardness 
11. Friability 
12. Assay 
13. Content Uniformity 
14. In-Vitro  Disintegration Time 
15. Simulated Wetting Time 
10.In-Vitro Dissolution Study 
VII) Kinetics of In-Vitro drug release of porous tablets 
VIII) Stability testing of selected formulation of porous tablets 
13) RESULTS AND DISCUSSION 
14) SUMMARY AND CONCLUSION 
15) FUTURE PROSPECTS 
 
 
 
 
 
  
LITERATURE  
 SURVEY 
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4. LITERATURE REVIEW 
 
Arun Arya, et al., (2010) published a review article deals with the history of the 
OTFs and a brief note on the OTF characteristic features including their advantages, 
composition, manufacturing methods, evaluating parameters. The article contains a 
new method for determination of dissolution rate called as conductivity method. 
Basani Gavaskar D.M., et al., (2010) aimed to compact the sources of OTFs to give 
a collective overview on the Oral Fast Dissolving Films in this work. The article 
consists of the general information like advantages and disadvantages, formulation, 
evaluation and marketed preparations of Oral Films. 
Brahmeswar Mishra, et al., (2009) wrote an overview on the Mouth Dissolving 
Drug Delivery systems. They primarily focused on the different formulation 
techniques and technologies that are using in the preparation of the Mouth Dissolving 
Drug Delivery systems. The article described very elaborately about each and every 
technology in a descriptive manner. They also included the patented technologies 
information that are using in the preparation of Oral Disintegrating Tablets. The 
article covers also the introduction about the Fast Dissolving Films. 
Chaudhari P.D., et al., (2007) made Levocetrizine orodispersible tablet by preparing 
their complexes. The complex of the drug made with the ion exchange resin, Tulsion 
335 (polyacrylic hydrogen with carboxylic functionality). Then the complex was 
formulated in to the orodispersible dosage form. The tablets were evaluated for 
various parameters like drug content, content uniformity, weight variation, hardness, 
friability, water absorption ratio, in-vitro, in-vivo disintegration time and in-vitro drug 
release. They found that the formulation containing the Tulsion was satisfactory for 
the taste mask and the results shown better disintegration and dissolution. 
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Debjit Bhowmik, et al., (2009) presented a comprehensive review on the Fast 
Dissolving Tablets which covers the ideal characteristics, limitations, manufacturing 
technologies, evaluation tests. The article also gives data about the mechanism of the 
tablet disintegration and list of the Fast Dissolving Tablets available in the market. It 
consists of list of superdisintegrants that can be used in the preparation of Fast 
Dissolving Tablets. 
Devi V.K., et al., (2006) prepared orodispersible tablets of Fluconazole with two 
different ingredients that are ammonium chloride and camphor (volatalizable 
compounds). Eight formulations were prepared with varying concentrations of these 
two ingredients. They used the wet granulation technique. These tablets were 
evaluated for different tests like friability, weight variation, hardness, disintegration 
time and pH of the solution after dispersion. They reported the best formulation by 
comparing the prepared tablets with each other and finally with the marketed 
conventional tablets. 
Gattani S.G., et al., (2009) developed Ondansetron mouth dissolving tablets. The 
approach selected for the rapid dissolving is superdisintegrant addition method. The 
superdisintegrants used in their study are Sodium starch glycolate, croscarmellose 
sodium and treated agar. The formulations containing superdisintegrants are compared 
with the blank formulation that does not contain the any superdisintegrant. The 
prepared formulations are checked for different evolutionary parameters and finally 
concluded that croscarmellose sodium is best disintegrant. 
Gohel M.C., et al., (2007) fabricated Valdecoxib oral films using different film 
forming polymers like Eudragit EPO and hydroxyl propyl methyl cellulose and in 
their combinations. The oral films were prepared by the film casting method. They 
used the glycerol; menthol and aspartame in their formulation as plasticizer, cooling 
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agent and sweetener. The films were cutted in to a convenient size in the size of 4 cm2 
area. The films were evaluated for different parameters like hydration study, folding 
endurance and in-vitro drug dissolution (in the distilled water) for optimization. They 
observed that the films containing the higher concentration of glycerol showed higher 
water uptake and faster drug release. 
Jae Han Park., et al., (2008) developed a method for the determination of the 
Disintegration time of the Oral Disintegrating Tablets. The method is useful in the 
place of USP disintegration test. It is a simple method can develop in lab scale. They 
used 22 mm diameter polystyrene microplate, Sensient blue dye and a Whatman filter 
paper for the test. The test is named as Simulated Wetting Time. 
Karthikeyan D., et al., (2008) developed modified ocular inserts of Indomethacin for 
the prolonged action and better patient convenience and the solvent casting technique 
was used for their formulation. Eudragit RS 100 and Ethyl cellulose were used as 
polymers and dichloromethane and dibutyl phthalate were used as solvent and 
plasticizer respectively. The formulations were evaluated for different parameters like 
drug- excipient interaction, Physico-chemical characteristics and stability studies. The 
best formulation was showed zero order release pattern. 
Kaushik D., et al., (2004) prepared the mouth dissolving tablets of Olanzapine drug. 
These selected effervescent formulation approach for the preparation. The 
effervescent excipient not only helps in faster disintegration but also masks the slight 
bitter taste of medicament. Sodium bicarbonate and citric acid were used as 
effervescent agents were selected in the work and their ratio in the formulation was 
optimized. The prepared formulations were evaluated for different parameters like 
hardness, disintegration, friability, dissolution etc., and best formulation was reported 
by using the disintegration time and dissolution behavior. 
TASTE  MASKED   POROUS   TABLETS  OF  LOSARTAN  POTASSIUM                         LITERATURE SURVEY 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR 48 
Mukesh Gohel., et al., (2004) designed Nimesulide mouth dissolving tablets. They 
used vacuum drying technique in the preparation of the mouth dissolve tablets. The 
vacuum drying technique produces a porous structure that can be facilitating the 
dissolution so they chosen this approach. They prepared tablets by wet granulation 
technique and the granule blend contains the crospovidone as a superdisintegrants and 
the camphor as a subliming agent. The concentration of the crospovidone was 
optimized by application of the 32 factorial approaches. The ordinary tablets were 
prepared by the using a sufficient compression force and later these were made porous 
by sublimation technique at 60°C.  The prepared tablets were evaluated for different 
parameters like hardness, friability, wetting time, drug content, water absorption ratio, 
in- vitro disintegration time and in-vitro drug release. Best formulation was finalized 
by the in- vitro drug release pattern. They concluded that vacuum drying can be used 
as an alternative method for the production of MDTs. 
Na Zhao, et al., (2005) were aimed to compare the disintegration efficiency and the 
development of a test model for the 3 classes of superdisintegrants what they were 
used in their present work. The 3 superdisintegrants used were as follows, Ac-Di-Sol, 
Primojel, and Polyplasdone XL. For the proto type formulation the 3 
superdisintegrants were made in to tablets with the incorporation of a traditional drug 
Aspirin. For the examining the disintegration of each tablet these used a novel 
approach i.e. Using a digital video camera. From this data they analyzed the best 
superdisintegrant by different statistical approaches and they found the Ac-Di-Sol 
tablets rapidly disintegrating comparing to other superdisintegrants. 
Nagendrakumar D., et al., (2009) prepared the Fexofenadine HCl Fast dissolving 
tablets. These selected effervescent formulation approach for the preparation. The 
effervescent agents used were sodium bicarbonate and the citric acid. The  
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superdisintegrants used were crospovidone, croscarmellose sodium and sodium starch 
glycolate. Sodium bicarbonate and citric acid ratio in the formulation was optimized. 
The prepared formulations were evaluated for different parameters like hardness, 
friability, drug content uniformity and in-vitro dispersion time and finally the best 
formulation among the prepared were compared with the commercial conventional 
tablet formulation. 
Panigahi Patel, et al., (2005) produced an article which covers a review on the 
Mouth Dissolving Tablets. The article covers the ideal characteristics, limitations, 
manufacturing technologies, evaluation tests. They described about the oral 
absorption test and different dissolution medias used in the evaluation of the MDTs. 
Rakesh Patel, et al., (2009) formulated an Ondansetron edible film. The film forming 
polymers selected in this study were low viscosity grade hydroxypropyl 
methylcellulose (HPMC E 15) and Maltodextrin and in their combination. They 
selected these because of their excellent film forming property and palatable taste. 
Glycerol and carragenan were added for their plasticizing and stabilizing properties. 
The films prepared from the high concentration of maltodextrin leads to formation of 
a brittle film, when compared with the film formations containing the lower 
concentration. In the same way the higher concentration of HPMC E 15 was resulted 
in sticky film formation. The best formulation that they reported after the all quality 
checking tests was the formulation containing 25%w/w Maltodextrin and HPMC E 15 
20%w/w. 
Ravi Kumar, et al., (2008) prepared Fast dissolving tablets of Captopril. These 
developed the tablets by two different approaches named as wow tab and effervescent 
technology. The excipients used in both the technologies not only aid fast 
disintegration of tablets, but also mask the slight bitter taste of drug. The sodium 
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bicarbonate and citric acid were used in the effervescent approach and the maltose and 
lactose were used in the wow tab technology. All the prepared formulations were 
evaluated for different quality control tests like thickness, friability, weight variation, 
drug content, and disintegration time and drug dissolution. Study has shown that 8:6 
ratio of sodium bicarbonate and citric acid in the Captopril fast dissolving tablets gave 
good soothing and excellent mouth feel. 
Renuka Mishra, et al., (2009) prepared Cetrizine rapid disintegrating films. The 
classes of polymers that are fast disintegrating and having good film-forming 
properties (e.g., hydroxypropyl methylcellulose [HPMC], Pullulan, and 
hydroxypropyl cellulose [HPC]) were taken in the preparation of films. Various 
grades of HPMC E LV (i.e., E3, E5, and E15) were taken into consideration. Out of 
available methods such as solvent casting, semisolid casting, hot melt extrusion, solid 
dispersion extrusion, and rolling the solvent casting technique was selected in their 
study for preparation of the films due to their advantages like common and traditional 
method. The prepared films of Cetrizine were checked for the tests like thickness, 
mechanical properties such as tensile strength and elasticity, in-vitro and in-vivo 
disintegration, and in-vitro dissolution. Out of the different grades of polymers that 
they selected the HPMC E 3LV was reported as most suitable polymer. 
Shastry C.S., et al., (2004) focused on different taste masking techniques because the 
taste is an important parameter in developing the oral dosage forms. The article 
describes different taste masking approaches that are using in the present 
pharmaceutical industries and list of some therapeutic agents that have bitter taste. 
The simple and cost efficient method out of these is sensory approach. 
Shirsand S.B., et al., (2010) designed a fast disintegrating tablet formulation of 
Prochlorperaziine by incorporation of disintegrants. They selected croscarmellose 
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sodium, crospovidone, and sodium starch glycolate as superdisintegrants and direct 
compression technique for preparing the tablets. 
Sumitha Ch., et al., (2009) prepared rapid disintegrating films (RDFs) of 
Ondansetron HCl to improve the patient convenience. The methocel E15 polymer was 
used as film forming polymer. The Ondansetron HCl was bitter drug so it was 
formulated as complexion with the ion exchange resin Polacriline Potassium. The 
Polacriline Potassium had disintegrating property. For more taste masking and patient 
convenient the authors used sweetener and flavors. For the flavoring instead of the 
single flavor three different flavors viz., vanilla, lychee and banana. The prepared 
formulations were evaluated for different quality tests. The formulation which does 
not release the drug in the saliva was selected for the best formulation. The 
formulation also shows the rapid release of the drug due to disintegration of the 
polymer methocel E15. 
Suresh Bandari, et al., (2008) presented a comprehensive review on the Oral 
Disintegrating Tablets. The review covers definition of ODTs, challenges in 
development, the ideal characteristics, limitations, manufacturing technologies, 
evaluation tests. The article also gives data about the mechanism of the tablet 
disintegration and list of the Oral Disintegration Tablets available in the Indian and 
International market. The article describes the various disintegration methods for 
evaluation of Oral Disintegration Tablets like rotator shaft method, sieve method. 
Suvakanta Dash, et al., (2009) wrote a review article on the release kinetics of the 
controlled drug delivery systems. The article gives information about the zero order 
release, first order release kinetic modeling with equations. 
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Literature review indicating work carried out on selected drug, Losartan 
potassium is given below: 
Sasidhar R.L.C, et al. (2010)  In the present investigation an attempt has been made 
to increase therapeutic efficacy, reduced frequency of administration and improved 
patient compliance by developing controlled release matrix tablets of Losartan 
Potassium. Losartan Potassium was formulated as oral controlled release matrix 
tablets by using poly (ethylene oxides) {Polyox WSR 303}.The aim of this study was 
to investigate the influence of polymer level and type if fillers namely lactose [soluble 
filler], microcrystalline cellulose and anhydrous dibasic calcium phosphate [insoluble 
fillers] on the release rate and mechanism of Losartan Potassium from matrix tablets. 
Rout Prasant kumar, et al. (2009) Present investigation describes preparation of 
microspheres prepared by solvent evaporation method followed by invitro 
characterization statistically. Microspheres containing Losartan potassium were 
prepared by solvent evaporation method by using ethyl cellulose and Acycoat L30D 
as rate controlling polymer. The microspheres were found to be discrete, spherical 
with free flowing properties. The morphology (Scanning Electron Microscopy), 
particle size distribution, total entrapment of Losartan potassium into the 
microparticles and their release profiles were investigated. 
Reena T, et al. (2009)  The purpose of the current study was to investigate the 
feasibility of proniosomes as transdermal drug delivery system for losartan potassium. 
Different preparations of proniosomes were fabricated using different nonionic 
surfactants, such as Span 20, Span 40, Span 60, Span 80, Tween 20, Tween 40, and 
Tween 80. Different formulae were prepared and coded as PNG-1 (proniosomal gel-1) 
to PNG-7. 
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Chopra S, et al. (2006)   The aim of the present research work was to systemically 
device a model of factors that would yield an optimized controlled release tablet 
dosage form of an anti-hypertensive agent, losartan potassium. Independent variables 
such as the amount of the release retardant polymers- Methocel K15M(X1), Methocel 
K100M(X2) and Sodium carboxy methyl cellulose(X3) were optimized using a 3-
Factor, 3-level Box-Behnken statistical design. The dependent variables selected were 
the burst release in 15min (Y1), cumulative % release of losartan potassium after 60 
min. (Y2) and hardness (Y3) of the tablets. 
Shruti C, et al. (2006)   The aim of the present research work was to systemically 
device a model of factors that would yield an optimized sustained release tablet 
dosage form of an anti-hypertensive agent, losartan potassium, using response surface 
methodology by employing a  3-Factor, 3-level Box-Behnken statistical design. 
Independent variables studied were the amount of the release retardant polymers-
HPMC K15M(X1), HPMC K100M(X2) and Sodiumcarboxy methylcellulose(X3). The 
dependent variables selected were the burst release in 15min.(Y1), cumulative % 
release of losartan potassium after 60 min. (Y2) and hardness(Y3) of the tablets with 
constraints on the Y2= 31-35%. 
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5.DRUG AND EXCIPIENTS PROFILE 
5.1. DRUG PROFILE 
Losartan potassium  (IP, 2007; BP, 2009; Merck Index, 1997; USP, 2009; Clark’s, 
2004; KD Tripathi, 2008) 
Losartan potassium is an angiotensin II receptor (type AT1) antagonist. 
Proprietery Name: ACTILOP, LOSCOM , LOSACAR. 
Molecular formula : C22H22ClKN6O, 
Molecular weight:  461.01 g/mole. 
Chemical name: 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-
5- methanol monopotassium salt. 
 Structural formula : 
 
Solubility: It is freely soluble in water, soluble in alcohols, and slightly soluble in 
common organic solvents, such as acetonitrile and methyl ethyl ketone. 
Category: Anti hypertensive drug. 
Dose:   25mg, 50mg. 
Melting point: 183.5-1840C. 
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PKa  :     5-6. 
Bioavailability : 33%. 
Angiotensin –II receptor subtype1 antagonist. 
Description:   Losartan potassium is a white to off-white free-flowing crystalline 
powder. It  is a non-peptide molecule. Oxidation of the 5 
hydroxymethyl group on the imidazole ring results in the active 
metabolite of losartan. 
Storage:  Store at 25°C 15-30°C Temperature]. Keep container tightly closed. 
    Protect from light. 
SIDE EFFECTS: 
Many  people  using this medication  do  not have serious side effects. 
          Fainting, decreased sexual ability, change in the amount of urine, 
stomach/abdominal pain, severe nausea, yellowing eyes or skin, dark urine, unusual 
fatigue, muscle pain. 
 Symptoms of an allergic reaction include: rash, itching, swelling (especially of the 
face, lips, tongue, or throat), severe dizziness, trouble breathing. 
Adverse events occurred at about the same rates in men and women, older and 
younger patients, and Black and non-Black patients. 
Superficial peeling of palms and hemolysis were reported in one subject. 
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CLINICAL PHARMACOLOGY: 
Mechanism of Action 
Angiotensin II [formed from angiotensin I in a reaction catalyzed by 
angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the 
primary vasoactive hormone of the renin-angiotensin system and an important 
component in the pathophysiology of hypertension. It also stimulates aldosterone 
secretion by the adrenal cortex. Losartan and its principal active metabolite block the 
vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively 
blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g., 
vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many 
tissues but it is not known to be associated with cardiovascular homeostasis. Both 
losartan and its principal active metabolite do not exhibit any partial agonist activity 
at the AT1 receptor and have much greater affinity (about 1000-fold) for the AT1 
receptor than for the AT2 receptor. In vitro binding studies indicate that losartan is a 
reversible, competitive inhibitor of the AT1 receptor. Neither losartan nor its active 
metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to 
angiotensin II and degrades bradykinin). 
Pharmacokinetics
 
Losartan is an orally active agent that undergoes substantial first-pass metabolism by 
cytochrome P450 enzymes. It is converted, in part, to an active carboxylic acid 
metabolite that is responsible for most of the angiotensin II receptor antagonism that 
follows losartan treatment. Losartan metabolites have been identified in human 
plasma and urine. In addition to the active carboxylic acid metabolite, several inactive 
metabolites are formed.The terminal half-life of losartan is about 2 
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hours.The pharmacokinetics of losartan and its active metabolite are linear with oral 
losartan doses up to 200 mg and do not change over time. Neither losartan nor its 
metabolite accumulate in plasma upon repeated once-daily dosing. 
Absorption: 
Following oral administration, losartan is well absorbed (based on absorption 
of radiolabeled losartan) and undergoes substantial first-pass metabolism; the 
systemic bioavailability of losartan is approximately 33%. 
Distribution: 
Both losartan and its active metabolite are highly bound to plasma proteins 
i.e., 98% plasma protein bound, primarily albumin, with plasma free fractions of 1.3% 
and 0.2%, respectively. Plasma protein binding is constant over the concentration 
range achieved with recommended doses. 
Elimination: 
           The terminal half-life of losartan is about 2 hours. 
Pharmacodynamics and Clinical Effects 
Adult Hypertension 
Losartan inhibits the pressor effect of angiotensin II (as well as angiotensin I) 
infusions. A dose of 100 mg inhibits the pressor effect by about 85% at peak with 25-
40% inhibition persisting for 24 hours. Removal of the negative feedback of 
angiotensin II causes a 2- to 3-fold rise in plasma renin activity and consequent rise in 
angiotensin II plasma concentration in hypertensive patients. Losartan does not affect 
the response to bradykinin, whereas ACE inhibitors increase the response to 
bradykinin. Aldosterone plasma concentrations fall following losartan administration.  
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In spite of the effect of losartan on aldosterone secretion, very little effect on 
serum potassium was observed. 
USES: 
This drug is used to treat high blood pressure (hypertension) and to help 
protect the kidneys from damage due to diabetes. It is also used to lower the risk of 
strokes in patients with high blood pressure and an enlarged heart. High blood 
pressure reduction helps prevent strokes, heart attacks, and kidney problems. This 
drug works by blocking the hormone angiotensin thereby relaxing blood vessels, 
causing them to widen. Losartan belongs to a class of drugs called angiotensin 
receptor blockers. 
OTHER USES: 
This drug may also be used to treat congestive heart failure. 
HOW TO USE:  Take this medication by mouth, usually once daily or as directed by 
your doctor. You may take this drug with or without foodIt is important to continue 
taking this medication even if you feel well. 
PRECAUTIONS: 
Before taking losartan, tell your doctor or pharmacist if you are allergic to it; 
or to ACE inhibitors (e.g., captopril, lisinopril); or if you have any other 
allergiesespecially of: kidney disease, liver disease, high blood levels of potassium, 
heart problems, severe dehydration (and loss of electrolytes such as sodium). 
This drug may make you dizzy; use caution engaging in activities requiring 
alertness such as driving or using machinery. Limit alcoholic beverages. 
PREGNANCY CONTRAINDICATIONS 
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This medication is not recommended for use during pregnancy due to the risk 
for harm to an unborn baby. Breast-feeding is not recommended due to the potential 
harm to the nursing infant. 
PATIENT INFORMATION: 
Pregnancy: 
Female patients of childbearing age should be told about the consequences of 
second- and third-trimester exposure to drugs that act on the renin-angiotensin system, 
and they should also be told that these consequences do not appear to have resulted 
from intrauterine drug exposure that has been limited to the first trimester. 
Potassium Supplements 
 A patient losartan potassium receiving should be told not to use potassium 
supplements or salt substitutes containing potassium without consulting the 
prescribing physician. 
DRUG INTERACTIONS: 
Digoxin, fluconazole, lithium, "water pills" (diuretics such as furosemide; 
potassium-sparing diuretics such as amiloride, spironolactone, triamterene), rifampin. 
As with other drugs that block angiotensin II or its effects, concomitant use of 
potassium-sparing diuretics  and potassium supplements, or salt substitutes containing 
potassium may lead to increases in serum potassium. A patient with known 
hypersensitivity to aspirin and penicillin, when treated with losartan, was withdrawn 
from study due to swelling of the lips and eyelids and facial rash, reported as 
angioedema, which returned to normal 5 days after therapy was discontinued. 
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MISSED DOSE: 
If you miss a dose, use it as soon as you remember. If it is near the time of the next 
dose, skip the missed dose and resume your usual dosing schedule. Do not double the 
dose to catch up. 
• Dosage Forms: 
• Tablet:          Actilop: 25mg, 50mg. 
• FC-Tablet :  Losapot: 25mg, 50mg. 
5.2. EXCIPIENTS PROFILE:    
a)CAMPHOR   (http://en.wikipedia.org/wiki/camphor) 
Nonproprietory name: None adopted. 
Synonyms:   Camfora ,alcanfor, root bark oil. 
Functional Category: Rubefacient,counter irritant. 
Empirical Formula: C10H16O   
Molecular Weight: 152.2 
Brand name: Camphora synthetic tablets,camphora. 
Description:    White   solid translucent crystals  Fine . 
odour : Aromatic.                                                                                                           
Typical Properties: 
 Solubility: Soluble in ethanol,turpentine and essential oils..        
Stability and storage conditions: 
  Not Stable , Store in a well closed container .   
 As it sublimes at room temperature.                                  
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Shelf life: five years 
b)THYMOL (http://en.wikipedia.org/wiki/thymol) 
Nonproprietary Names:B.P:Thymol,  USPNF:Thymol,  PhEur:Thymolum. 
Synonyms:Acidotrimico;Flavinol,intrasol,isopropylcresol,isoproply 
metacresol,timol,m-thymol,thymic acid. 
Chemical Name: Thymol 
CAS Registry Number: [89-83-8] 
Empirical Formula  : C10H14O 
Molecular Weight : 150.24 
Functional Category :Antioxidant,antiseptic,disinfectant,flavouringagent,therapeutic 
agent,skin penetrant. 
Applications in Pharmaceutical Formulation or Technology: 
Thymol is a phenolic antiseptic,which has anyibacterial and antifungal 
activity.Thymol is more powerfull disinfectant than phenol,but its low water 
solubility,its irritancy to tissues,and its inactivation due to organic material,such as 
proteins,limits its use as disinfectant.Thymol is chiefly used as a deodrant in 
antiseptic. 
Solubility: Soluble in ethanol,chloroform,ether,glacial acetic acid,essential oils ,fixed 
oils and fats.sparingly soluble in glycerin. 
Incompatibilities: Thymol is incompatible with iodine,alkalis and oxidising agent. 
Stability and storage: Thymol should be stored in well closed ,light resistant 
containers,in cool,dry place.Thymol is affected by light. 
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c)MENTHOL  (Raymond C. Rowe, 2003) 
Nonproprietary Names: B.P:Racementhol,  USP:Menthol,  PhEur:Mentholum 
racemicum. 
Synonyms: Hexahydrothymol,peppermint camphor,racemic menthol,dl-menthol,3-p 
menthanol,p-menthan -3-ol. 
Chemical Name: (1RS,2RS,5RS)-(Æ)-5-Methyl-2-(1-methylethyl)cyclohexanol 
[15356-70-4] . 
Empirical Formula  : C10H20O 
Molecular Weight : 156.27 
Functional Category : Flavouring   agent,therapeutic agent. 
Applications in Pharmaceutical Formulation or Technology: 
 Menthol is widely used in pharmaceuticals, confectionery, and toiletry 
products as a flavoring agent or odour enhancer. In addition to its characteristic 
peppermint flavor, l-menthol, which occurs naturally, also exerts a cooling or 
refreshing sensation that is exploited in many topical preparations. Unlike mannitol, 
which exerts a similar effect due to a negative heat of solution, l-menthol interacts 
directly with the body’s coldness receptors. d-Menthol has no cooling effect, while 
racemic menthol exerts an effect approximately half that of l-menthol. When used to 
flavor tablets, menthol is generally dissolved in ethanol (95%) and sprayed onto tablet 
granules and not used as a solid excipient. 
Solubility: very soluble in ethanol (95%), chloroform, ether, fatty oils and liquid 
paraffin; soluble in acetone and benzene; very slightly soluble in glycerin; practically 
insoluble in water. 
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Incompatibilities: Incompatible with: butylchloral hydrate; camphor; chloral hydrate; 
chromium trioxide; b-naphthol; phenol; potassium permanganate; pyrogallol; 
resorcinol; and thymol.   
Stability and storage: A formulation containing menthol 1% w/w in aqueous cream 
has been reported to be stable for up to 18 months when stored at room 
temperature.(1) 
Menthol should be stored in a well-closed container at a temperature not exceeding 
258C, since it sublimes readily. 
d)AMMONIUMBICARBONATE(http://en.wikipediaorg/wiki/Ammonium_bicarbonate) 
Nonproprietary Names: Ammonium bicarbonate. 
Synonyms: Sal volatile, salt of hartshorn, baking soda, baking powder. 
Synonyms: Bakers ammonia. 
Chemical Name: Ammonium bicarbonate. 
Functional Category :Leavening agent. 
Applications in Pharmaceutical Formulation or Technology: 
 It is used as an emetic.As well as smelling agent,it is used as leavening agent 
till today, particularly in recipes.Ammonium bicarbonate is also found in smokeless 
tobacco products such as skoal. Buckleys cough syrup from canada uses ammonium 
bicarbonate as active ingredient which relieves bronchitis. 
Solubility: Very soluble water and alcohol,bicarbonate is not soluble in alcohol.  
Stability and storage: Store in well closed container as it sublimes easily. 
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e)CROSPOVIDONE: (Raymond C Rowe, 2003) 
Nonproprietary Names 
• BP: Crospovidone 
• PhEur: Crospovidonum 
• USPNF: Crospovidone 
Synonyms :  Crosslinked povidone, Kollidon CL, Kollidon CL-M, Polyplasdone  XL, 
PolyplasdoneXL-10, polyvinylpolypyrrolidone. 
Chemical Name: 1-Ethenyl-2-pyrrolidinone homopolymer 
CAS Registry Number: [9003-39-8] 
Functional Category: Tablet disintegrant. 
Applications in Pharmaceutical Formulation or Technology: 
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent 
used at 2–5% concentration in tablets prepared by direct-compression or wet- and dry-
granulation methods. It rapidly exhibits high capillary activity and pronounced 
hydration capacity,with little tendency to form gels. Studies suggest that the particle 
size of crospovidone strongly influences disintegration of analgesic tablets.7 Larger 
particles provide a faster disintegration than smaller particles. Crospovidone can also 
be used as a solubility enhancer. With the technique of co-evaporation, crospovidone 
can be used to enhance the solubility of poorly soluble drugs. The drug is adsorbed on 
to crospovidone in the presence of a suitable solvent and the solvent is then 
evaporated. This technique results in faster dissolution rate. 
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Description: Crospovidone is a white to creamy-white, finely divided, free-flowing, 
practically tasteless, odorless or nearly odorless, hygroscopic powder. 
Typical Properties 
Acidity/alkalinity:        pH = 5.0–8.0 (1% w/v aqueous slurry) 
Density:                         1.22 g/cm3 
Moisture content:Maximum moisture sorption is approximately 60%. 
Solubility:   Practically insoluble in water and most common organic solvents. 
Stability and Storage Conditions: Crospovidone is hygroscopic; it should be stored 
in an airtight container in a cool, dry place. 
Incompatibilities: Crospovidone is compatible with most organic and inorganic 
pharmaceutical ingredients. When exposed to a high water level, crospovidone may 
form molecular adducts with some Materials. 
f)MICROCRYSTALLINE CELLULOSE : (Raymond C. Rowe, 2003) 
Nonproprietary Names:     
BP: Microcrystalline cellulose 
JP: Microcrystalline cellulose 
PhEur: Cellulosum microcristallinum 
USPNF: Microcrystalline cellulose 
Synonyms: Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline 
cellulose;   
                  E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur. 
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Chemical Name: Cellulose 
CAS Registry Number: [9004-34-6] 
Molecular Weight: 36 000 
Functional Category: 
Adsorbent;  suspending agent;  tablet and capsule diluent; tablet disintegrant. 
Description: 
Microcrystalline cellulose is a purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications. 
Typical Properties: 
Density (bulk):                 0.337 g/cm3; 
Density (tapped):            0.478 g/cm3; 
Density (true):                       1.512–1.668 g/cm3 
Flowability:                           1.41 g/s 
Melting point:                       chars at 260–270°C. 
Specific surface area:           1.06–1.12 m2/g for Avicel PH-101; 
                                                1.21–1.30 m2/g for Avicel PH-102; 
                                                 0.78–1.18 m2/g for Avicel PH-200. 
                                                 1.21–1.30 m2/g for Avicel PH-102; 
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Moisture content: Typically less than 5% w/w. However, different grades may 
contain varying amounts of water. Microcrystalline cellulose is hygroscopic. (Avicel 
PH- 102= ≤5.0) 
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution; practically 
insoluble in water, dilute acids, and most organic solvents. 
Applications in Pharmaceutical Formulation or Technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and directcompression processes.  Microcrystalline cellulose also has 
some lubricant and disintegrant properties that make it useful in tableting. 
Uses of microcrystalline cellulose 
1.Adsorbent 
2.Capsule binder/diluents 
3.Tablet disintegrants 
4.Tablet binder/diluents 
Stability and Storage Conditions: Microcrystalline cellulose is a stable though 
hygroscopic material. The bulk material should be stored in a well-closed container in 
a cool, dry place. 
Incompatibilities: Microcrystalline cellulose is incompatible with strong oxidizing 
agents. 
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g)MANNITOL  (Raymond C. Rowe, 2003) 
Nonproprietary Names     
• BP: Mannitol 
• JP: D-Mannitol 
• PhEur: Mannitolum 
• USP: Mannitol 
Synonyms: Cordycepic acid, C*PharmMannidex, manna suga, D-mannite, Pearlitol. 
Chemical Name:              D-Mannitol 
CAS Registry Number:  [69-65-8] 
Empirical Formula:        C6H14O6 182.17 
Functional Category: Diluent; diluent for lyophilized preparations; sweetening 
agent; tablet and capsule diluent; tonicity agent. 
Applications in Pharmaceutical Formulation or Technology: 
• Mannitol is widely used in pharmaceutical formulations and food products. 
• In pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) 
in tablet Formulations. 
16) Mannitol may be used in direct-compression tablet applications. 
In lyophilized preparations, mannitol (20–90% w/w) has been included as a carrier to 
produce a stiff, homogeneous cake that improves the appearance of the lyophilized 
plug in a vial. Mannitol has also been used to prevent thickening in aqueous antacid  
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suspensions of aluminum hydroxide (<7% w/v). It has been suggested as a 
plasticizer in soft-gelatin capsules, as a component of sustained-release tablet 
formulations Density (bulk): 
• 0.430 g/cm3 for powder; 
• 0.7 g/cm3 for granules. 
Density (tapped): 
• 0.734 g/cm3 for powder; 
• 0.8 g/cm3 for granules. 
Density (true):   1.514 g/cm3 
Melting point:   166–168°C. 
Stability and Storage Conditions: 
Mannitol is stable in the dry state and in aqueous solutions. Solutions may be 
sterilized by filtration or by autoclaving and if necessary may be autoclaved 
repeatedly with no adverse physical or chemical effects. In solution, mannitol is not 
attacked by cold, dilute acids or alkalis, nor by atmospheric oxygen in the absence of 
catalysts. Mannitol does not undergo Maillard reactions. 
h)ASPARTAME : (Raymond C. Rowe, 2003) 
Nonproprietary Names     
• BP: Aspartame 
• PhEur: Aspartamum 
TASTE  MASKED  POROUS  TABLETS OF LOSARTAN POTASSIUM                 DRUG AND EXCIPIENTS PROFILE 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR 70 
• USPNF: Aspartame 
Synonyms 
 3-Amino-N-(α-carboxyphenethyl)succinamic acid N-methyl ester 
 3-amino-N-(α-methoxycarbonylphenethyl)succinamic acid 
 Aspartyl phenylamine methyl ester; 
Chemical Name:           N-α-L-Aspartyl-L-phenylalanine 1-methyl ester. 
CAS Registry Number: [22839-47-0] 
Empirical Formula:      C14H18N2O5 
Functional Category:    Sweetening agent. 
Applications in Pharmaceutical Formulation or Technology: 
3. Aspartame is used as an intense sweetening agent in beverage products, food 
products, and table-top sweeteners, and in pharmaceutical preparations including 
tablets,powder mixes, and vitamin preparations. 
4. It enhances flavor systems and can be used to mask some unpleasant taste 
characteristics; the approximate sweetening power is 180–200 times that of sucrose. 
5. Unlike some other intense sweeteners, aspartame is metabolized in the body 
and consequently has some nutritive value: 1 g provides approximately 17 kJ (4 kcal). 
Therapeutically, aspartame has also been used in the treatment of sickle cell anemia 
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i)TALC:  (Raymond C. Rowe, 2003) 
Nonproprietary Names: BP Purified talc; IP Talc; PhEur Talcum; USP Talc. 
Synonyms: Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil Star; powdered talc;purified French chalk; Purtalc; soapstone; steatite; 
Superiore. 
Chemical Name and CAS Registry Number: Talc [14807-96-6] 
Empirical Formula and Molecular Weight: Talc is a purified, hydrated, magnesium 
silicate, approximating to the formula Mg6(Si2O5)4(OH)4. It may contain small, 
variable amounts of aluminum silicate and iron. 
Functional Category: Anticaking  agent; glidant; tablet and capsule diluent; tablet 
and capsule lubricant. 
Applications in Pharmaceutical Formulation or Technology: Talc was once widely 
used in oral solid dosage formulations as a lubricant and diluents. 
Uses in Concentration (%) 
 Dusting powder 90.0 to 99.0 
 Glidant and tablet lubricant 1.0 to 10.0 
 Tablet and capsule diluent 5.0 to 30.0 
Although today it is less commonly used. However, it is widely used as a dissolution 
retardant in the development of controlled-release products.  Talc is also used as a 
lubricantin tablet formulations; in a novel powder coating for extended-release pellets; 
and as an adsorbant. In topical preparations, talc is used as a dusting powder, although 
it should not be used to dust surgical gloves. Talc is a natural material; it may 
therefore frequently contain microorganisms and should be sterilized  
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when used as a dusting powder. Talc is additionally used to clarify liquids and 
is also used in cosmetics and food products, mainly for its lubricant properties. 
Description: Talc is a very fine, white to grayish-white, odorless, impalpable, 
unctuous, crystalline powder. It adheres readily to the skin and is soft to the touch and 
free from grittiness. 
Typical Properties 
Acidity/alkalinity: pH = 7 - 10 for a 20% w/v aqueous dispersion. 
Hardness (Mohs): 1.0 - 1.5 
Moisture content: Talc absorbs insignificant amounts of water at 25°C and relative 
humidities up to about 90%. 
Particle size distribution: Pharmaceutical Excipients 2215 varies with the source and 
grade of material. Two typical grades are = 99% through a 74 µm (#200 mesh) or 
=°99% through a 44 µm (#325 mesh). 
Solubility: Practically insoluble in dilute acids and alkalis, organic solvents and 
water. 
Specific gravity: 2.7–2.8 
Specific surface area: 2.41–2.42 m2/g 
Stability and Storage Conditions: Talc is a stable material and may be sterilized by 
heating at 160°C for not less than 1 hour. Talc should be stored in a well-closed 
container in a cool, dry place. 
Related Substances: Bentonite; magnesium aluminum silicate; magnesium silicate; 
magnesium trisilicate. 
Comments: Various different grades of talc are commercially available that vary in 
their chemical composition depending upon their source and method of preparation. 
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j)MAGNESIUM STEARATE (Raymond C. Rowe, 2003) 
Nonproprietary Names :     
1. BP: Magnesium stearate 
2. JP: Magnesium stearate 
3. PhEur: Magnesii stearas 
4. USP: Magnesium stearate 
Synonyms : Magnesium octadecanoate, stearic acid magnesium salt, 
                                           octadecanoic acid, magnesium salt 
Chemical Name :  Octadecanoic acid magnesium salt 
CAS Registry Number : 557-04-0 
Empirical Formula : C36H70MgO4 
Molecular Weight : 591.34 
Structural Formula : [CH3(CH2)16COO]2Mg 
Functional Category : Tablet, capsule lubricant 
Applications in Pharmaceutical Formulation or Technology: 
Magnesium stearate use was reported not only in the pharmaceuticals, but also 
in the cosmetics, and food products. 
The major action of the Magnesium stearate is lubricant. In 0.25-5.0 percent 
concentration it acts as lubricant in capsule and tablet manufacturing. 
The use of magnesium stearate in creams also reported. 
Description: Magnesium stearate is a fine, white, precipitated or milled, impaltable 
powder. It haves low bulk density. It had a faint odor of stearic acid. The taste of 
magnesium stearate is characteristic. It is greasy to touch. 
Handling Precautions: While handling the magnesium stearate eye protection and 
gloves are recommended. 
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6. MATERIALS AND EQUIPMENTS 
 
                 Table 6.1 : List of Materials and their Suppliers 
S. No. Name of Raw Materials Name of the Supplier 
1. Losartan potassium Actavis Pharmaceuticals, Chennai. 
2. Camphor Concept Pharmaceuticals, Aurangabad. 
3. Crospovidone Concept Pharmaceuticals, Aurangabad. 
4. Thymol Concept Pharmaceuticals, Aurangabad. 
5. Menthol Qualigens Fine Chemicals, Mumbai. 
6. Ammonium Bicarbonate Loba Chemie Pvt. Ltd., Mumbai. 
7. Mannitol Loba Chemie Pvt. Ltd., Mumbai. 
8. Aspartame GK Labs, Acharapakkam. 
9. Pineapple Flavor GK Labs, Acharapakkam. 
10. Magnesium Stearate Loba Chemie Pvt. Ltd., Mumbai. 
11. Microcrystalline Cellulose PH 102 Loba Chemie Pvt. Ltd., Mumbai. 
12. Talc GK Labs, Acharapakkam. 
13. Hydrochloric Acid Loba Chemie Pvt. Ltd., Mumbai. 
14. Methanol Loba Chemie Pvt. Ltd., Mumbai. 
15. Acetone Loba Chemie Pvt. Ltd., Mumbai. 
16. Ethanol Qualigens Fine Chemicals, Mumbai. 
17. Sodium Hydroxide Loba Chemie Pvt. Ltd., Mumbai. 
18. Potassium di Hydrogen Phosphate Loba Chemie Pvt. Ltd., Mumbai. 
19. Sensient Blue Qualigens Fine Chemicals, Mumbai 
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                   Table 6.2 :  List of equipments used and manufacturers 
S. No. Name of Equipments Company Model 
1. Differential Scanning Calorimeter Shimadzu, Japan. DSC 60 
2. Digital pH Meter Elico Scientifics, Mumbai. L1610 
3. Electronic Balance Shimadzu, Japan. BL-220H 
4. Friability Apparatus Veego scientific, Mumbai. VFT-DV 
5. FTIR Spectrophotometer Shimadzu, Japan. S4008 
6. Hardness Tester Monsanto. - 
7. Hot Air Oven Chemi Equipments, Bombay. P-1401 
8. Humidity Chamber Labtech, Ambala. _ 
9. Melting Point Apparatus GUNA Enterprises, Chennai. _ 
10. Sixteen stage tablet Compression Machine 
Cadmach, Ahmadabad, 
India. JMD-4-8 
11. Standard Sieve             (20 and 40#) Jayant scientific, India. 
_ 
 
12. USP Tablet Disintegration Apparatus Veego scientific, Mumbai. VTD-DV 
13. USP Tablet Dissolution Apparatus Type II Veego scientific, Mumbai. VDA-8DR 
14. UV Spectrophotometer Shimadzu, Japan. 
UV Pharmaspec 
1700 
15. Vernier Caliper Indolab, Mitutoyo. - 
 
  
 
EXPERIMENTAL 
WORK 
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7.EXPERIMENTAL WORK 
7.1. PRELIMINARY STUDIES: 
The preliminary studies include testing of different physical and chemical 
properties of drug including its purity. 
7.1.1. Identification of Drug:  
7.1.1.1. Identification by FTIR Spectroscopy:    (Skoog D.A. et al., 1996; Robert 
M. Silverstein and Fransis S. Webster, 2003)   
The FTIR Spectrum was generally used as an identification by the chemical 
structure of a compound.  
A small quantity of sample was mixed with sufficient potassium bromide and 
compressed into a pellet by applying a 10 tons pressure with help of a hand operated 
press. This pellet was kept in a sample holder and scanned from 4000 to 400 cm-1. 
7.1.1.2. Identification by Melting Point: (IP, 2007) 
It was a simple primary physical test tested to test the purity of the drug. This 
parameter was analyzed by use of a laboratory melting point apparatus (Guna 
enterprises, Chennai) with a procedure stated in the Indian Pharmacopoeia, 2007. 
7.1.2. Physico-chemical Parameters: 
7.1.2.1.OrganolepticProperties: (Lachman.L.et al.,1991)                                                
  The Organoleptic properties like physical state, color, odor etc., of the drug 
were reported with help of the descriptive terminology. The drug is identified by  a 
simple procedure. 
7.1.2.2. Solubility Study:   (IP, 2007) 
The solubility of pure drug was determined in various solvents in order to select the 
solvents for the various analytical progresses and it is also important in the 
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therapeutic response. The solubility of drug was tested by micropipette method and 
results were reported by using various descriptive terminology specified in IP, 2007. 
7.1.3. Analytical Methods: 
7.1.3.1. Determination of  λ max    (Shankar Avulapati .et al.,2011) 
              The absorption maximum of the standard solution was scanned between 200-
400 nm regions on Shimadzu-1700 UV spectrophotometer. The absorption maximum 
obtained with the substance being examined corresponds in  the position. 
7.1.3.2. Preparation of standard graph of Losartan potassium 
7.1.3.2.1. Preparation of solutions: 
7.1.3.2.2. Preparation of pH  6.8 phosphate buffer: (IP, 2007) 
Phosphate buffer pH 6.8 was prepared according to I.P. 2007. Placed 50ml of 0.2M 
potassium dihydrogen phosphate in a 200ml  volumetric flask and 22.4ml of 0.2M 
sodium hydroxide was added and volume was made upto required quantity with 
water. 
7.1.3.2.3. Preparation of stock solution of Losartan potassium with pH 6.8 
phosphate buffer: 
           Accurately weighed 25 mg of Losartan potassium was dissolved in little 
quantity of  pH   6.8 buffer solution and volume was made upto 25ml,from that  
solution 10ml was adjusted to 100ml with phosphate buffer to prepare standard 
solution.   
7.1.3.2.4. Procedure: 
         From the stock solution, aliquots of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 ml were 
transferred to 25 ml volumetric flasks and final volume was made to 25 ml with pH  
6.8 phosphate buffer. Absorbance values of these solutions were measured against 
blank (pH 6.8 buffer) at 206nm using Shimadzu-1700 UV spectrophotometer. 
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7.2. DETERMINATION OF DRUG AND EXCIPIENTS COMPATIBILITY:  
(Robert M. Silverstein and Fransis S., 2003) 
It is a primary identification test to know the compatibility of the drug with the 
excipients used in the formulation. Some substances, like talc flavors etc., used in the 
formulation does not need to check the compatibility because of their inertness. There 
are so many methods to report the compatibility out of that FTIR and DSC studies 
were taken into consideration to check and report the compatibility. 
7.2.1. Fourier transforms Infra-Red (FTIR) spectroscopy   (IP, 2007) 
FTIR study was carried out to check compatibility of drug with polymers. Infrared 
spectrum of Losartan potassium was determined using Spectrophotometer using KBr 
dispersion method. The base line correction was done using dried potassium bromide. 
Then the spectrum of dried mixture of drug and potassium bromide was run followed 
by drug with various polymers by using Parkin elmer-Pharmaspec-1 FTIR 
spectrophotometer.   
7.2.2. Differential Scanning Calorimetry (DSC):                             
Differential scanning calorimetry (Shimadzu, Japan) was used to examined the 
thermal behaviour of pure drug and drug additive mixtures. Compatibility studies 
were carried on samples of 1:1 physical mixtures of the drug(Losartan Potassium) 
with various excipients viz...crosspovidone, avicel etc. The 2 mg of sample were 
heated in a hermetically sealed aluminum pans in the temperature range of 25-300ºC 
at heating rate of 10ºC /min under nitrogen flow of 30 ml/min. 
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7.3. PREPARATION AND EVALUATION OF POWDER BLEND: 
(Nagendrakumar D. et al., 2009; Swamy P.V et al., 2009) 
7.3.1. Preparation of Powder Blend: 
 All the ingredients mentioned in Table 7.3 were weighed and sifted through 
#44 mesh separately (crosspovidone and avicel made anhydrous by heated at a 
temperature of 60ºC for 30 minutes in hot air oven). The ingredients after sifting 
through sieve No. 44 were thoroughly blended except magnesium stearate in mortar 
and pestle for 15 min. Finally magnesium stearate was added as a lubricant and mixed 
thoroughly, and then each powder blend was stored in polythene bag individually. The 
batch size for each powder blend was 100 tablets. The prepared powder blends were 
evaluated for micromeritic properties before tablet compression. 
7.3.2. Evaluation of Micromeritic Properties of Powder Blend: (Lachman L. et al., 
1987; Aulton M.E., 2007; Ansel S.C. et al., 2009 , Shankar Avulapati .et 
al.,2011) 
7.3.2.1. Angle of Repose: 
It was “an indirect method for the determination of flowability of powder/ 
granules”, because of their relationship with the inter-particulate cohesion.  
Table 7.1 Relationship between Angle of Repose and Flowability 
S. No. Angle of Repose(°) Flowability 
1. < 25 Excellent 
2. 25 - 30 Good 
3. 30 - 40 Passable 
4. 37 - 45 Poor 
5. > 45 Very Poor 
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Method: 
A funnel was fitted to a burette stand at a distance of 8cm to 10cm from the 
horizontal plane to the brim. The test sample was filled in the funnel and made 
allowed through the small opening of funnel on a graph sheet. The flow forms a 
pile/cone on the graph paper. The height and radius of pile were measured by help of a 
scale. Angle of Repose (θ) was calculated with help of the following formula: 
 
Where, ‘h’ is the height of the pile 
             ‘r’ is the radius of the pile 
7.3.2.2. Bulk Density and Tapped Bulk Density: 
Bulk Density was defined as “the ratio of mass of a powder/granules and the 
bulk volume of powder/granules”. It also called as Loose Bulk Density (LBD). 
Tapped Bulk Density (TBD) was defined as “the ratio of the mass of a 
powder/granules and the tapped volume of powder/granules”. 
These parameters are primarily effect by different parameters like the distribution of 
same size particles, shape of particles, and adherence of particles with other. 
Method: 
An accurately weighed quantity of powder from each formulation was passed 
through the sieve #40 with light shaking (to break any agglomerates formed in 
mixing). 
Then the blend was introduced into a graduated cylinder. After the initial 
volume was observed, the cylinder was allowed to tap in away as it moves under its 
own weight onto a hard flat surface from the height of 2.5 cm at two second intervals. 
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The tapping was continued until no further change in volume was noted as 
tapped volume. 
LBD and TBD were calculated using the following formulas: 
           
          
 
7.3.2.3. Bulkiness: 
This parameter was to check uniformity of bulk chemicals. The bulkiness was 
determined by using following formula, 
                              
7.3.2.4. Hausner’s Ratio:                                                         
Hausner’s Ratio was defined as “ratio of tapped bulk density and loose bulk 
density”. It was determined by following equation, 
                               
Where, TBD is Tapped Bulk Density 
  LBD is Loose Bulk Density 
A  Hausner’s  Ratio less than 1.2 indicates good flow while greater than 1.6 
indicates poor flow of powders. 
7.3.2.5. Carr’s Compressibility Index: 
Compressibility was an important measure that can be obtained from the LBD 
and TBD. The compressibility index of the granules was determined by Carr’s 
Compressibility Index. It can be determined by following formula, 
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Where, TBD is Tapped Bulk Density 
  LBD is Loose Bulk Density 
The relationship of flow with the Carr’s Compressibility Index was depicted in 
Table 7.2. 
    Table 7.2 Relationship between Carr’s Compressibility Index and Flowability 
S. No. Carr’s Compressibility Index (%) Type of Flow 
1. 5 - 15 Excellent 
2. 12 - 16 Good 
3. 18 - 21 Fair to Passable 
4. 23 - 35 Poor 
5. 33 - 38 Very Poor 
6. > 40 Extremely Poor 
 
7.4. FORMULATION: 
7.4.1. Preparation of Porous Tablets: (Swamy P.V. et al., 2009; Ravi kumar et al., 
2008; Kaushik D. et al., 2004) 
The Porous Tablets of (25mg Losartan potassium) were prepared by direct 
compression. 
Formula for different formulations of Losartan potassium Porous Tablets was 
listed in Table 7.3. 
The powder blend was directly compressed into tablets having average weight 
of 200mg using a sixteen station tablet punching machine (Cadmach, Ahmedabad, 
India.) fitted with 9 mm round, one side break line flat punches. 
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Due to presence of the hygroscopic materials (Sublimation agents ) the de-
humidifier was used throughout the compression time to maintain the desired 
humidity conditions in the compression room. 
The die capacity was adjusted in order to get a 200 mg Porous Tablet and the 
compression force was kept as constant to produce hardness of the tablets at 2.5 
kg/cm2. 
Table 7.3 Formulation Table of Porous Tablets of Losartan potassium 
S. 
No. 
Ingredients 
(mg) 
Formulation Code with Quantities in mg 
FT1 FT2 FT3 FT4 FT5 FT6 FT7 FT8 FT9 
1. Losartan potassium 25 25 25 25 25 25 25 25 25 
2. Camphor 25 50 - - - - - - - 
3. Ammonium bicarbonate - - 25 50 - - - - - 
4. Menthol - - - - 25 50 - - - 
5. Thymol - - - - - - 25 50 - 
6. Avicel 5 5 5 5 5 5 5 5 5 
7. Mannitol 126 101 126 101 126 101 126 101 151 
8. Crosspovido
ne 
5 5 5 5 5 5 5 5 5 
9. Talc 2 2 2 2 2 2 2 2 2 
10. Aspartame 5 5 5 5 5 5 5 5 5 
11. Magnesium Stearate 4 4 4 4 4 4 4 4 4 
12. Pineapple flavor 3 3 3 3 3 3 3 3 3 
Total Weight 200 200 200 200 200 200 200 200 200 
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7.5. EVALUATION: 
7.5.1. Evaluation of porous tablets: 
7.5.1.1. Appearance      (Lachman L.,et al.,1991; Bankar G.S. and Rhodes C.T.,1996) 
The tablets were visually observed for capping, chipping, lamination and colour. 
7.5.1.2. Thickness and Diameter Test: (IP, 2007) 
Thickness and Diameter test permits accurate measurement and provides 
information on the variation between tablets. Ten tablets were taken and the thickness 
and diameter was measured using a vernier caliper. The tablet thickness and diameter 
should be controlled within a 5% variation of a standard value. 
7.5.1.3. Weight Variation Test:  (IP, 2007) 
To find out weight variation 20 tablets of each formulation were weighed 
individually using an electronic balance, average weight was calculated and 
individual tablet weight was then compared with average value to find the deviation 
in weight. The specifications were given in Table 7.4. 
Table 7.4 Specifications of %Weight Variation Allowed in Tablets as per 
Indian Pharmacopoeia 
S. No. Average Weight of Tablets (mg) Maximum Percent Deviation 
Allowed (%) 
1. 80 or less 10 
2. More than 80 but less than 250 7.5 
3. More than 250 5 
7.5.1.4. Hardness Test:   (IP, 2007) 
Hardness indicates “the ability of a tablet to withstand mechanical shocks 
while handling”. The hardness of the tablets was determined using Monsanto 
TASTE   MASKED   POROUS   TABLETS  OF  LOSARTAN POTASSIUM                    EXPERIMENTAL WORK 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR  85  
Hardness Tester. The force needed to disrupt them by crushing in kg/cm2 
expresses it. Six tablets were randomly picked from each formulation and the mean 
and standard deviation values were calculated. 
7.5.1.5. Friability Test: (IP, 2007) 
It is the phenomenon whereby tablet surfaces are damaged and/or show 
evidence of lamination or breakage when subjected to mechanical shock or attrition. 
The friability of tablets was determined using Roche Friabilator. 
Tablets about 20nos were initially weighed and transferred into friabilator. The 
friabilator was operated at 25 rpm for 4 minutes or run up to 100 revolutions. The 
tablets were weighed again. The % friability was then calculated by, 
 
Percent friability of tablets less than 1% are considered as acceptance. 
 
7.5.1.6. Assay:   (IP, 2007)   
Content uniformity was determined by accurately weighing 20 tablets and 
crushing them in mortar. Then an accurately weighed quantity of powder equivalent to 
20 mg of drug was transferred to a 100 ml volumetric flask. Few ml of water was 
added and shaken for 15 min. Volume was made up to 100 ml with distilled water. 
The solution was filtered through Whatmann filter paper.  5 ml of the filtrate was 
diluted to 100 ml with pH  6.8 phosphate buffer. Then absorbance of the resulting 10 
µg/ml solution was recorded at 206nm from which conent of drug was calculated. 
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7.5.1.7. Content Uniformity:         ( USP, 2009) 
This test is applicable to tablets that contain equivalent or less than 10 mg or 
less than 10% w/w of active ingredient. The test content uniformity carried out by 
taking the 5 individual tablets from each formulation batch and in that selected tablets 
the drug content was calculated by the procedure given in the assay of Porous Tablets 
individually.    
7.5.1.8. In-Vitro Disintegration Time: (Na Zhao et al., 2005; Shankar Avulapati .et 
al.,2011, USP, 2009) 
This test was performed to ensure disintegration of tablets in saliva. For the 
determination of In-Vitro disintegration time six tablets were randomly selected from 
each formulation and one tablet is introduced in to one tube of USP disintegration test 
apparatus and a disc was added into the each tube. The assembly was then suspended 
in the beaker containing pH 6.8 phosphate buffer solution. The tubes were then raised 
and lowered through a distance of 5.3 to 5.7 cm in buffer solution maintained at 37° ± 
2°C. The time taken for complete disintegration of the tablet with no palpable mass 
remaining in the apparatus was measured in seconds. The average time of six tablets 
to complete disintegration was reported as in-vitro disintegration time. The test was 
carried out by using United States Pharmacopoeia (USP) Disintegration Test 
Apparatus model Veego VTD-DV. 
7.5.1.9. Simulated Wetting Time (SWT):   (Jae Han Park et al., 2008) 
The wetting time of the ODTs was evaluated using the method described 
below. The method is called the "Simulated Wetting Test". One Whattman filter paper 
disc (21 mm in diameter) was placed in each well of a cup (22 mm in diameter). A 
volume 1.25 ml of 0.1% (w/w) Sensient Blue Dye solution was then added into cup.A 
rapimelt Tablet was carefully placed on the surface of the wet paper disk in cup using 
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a pair of forceps. The flat tablet face was in contact with the filter paper, and the level 
of the dye solution did not cover the tablet. The total wetting time was measured, 
defined as the time required for the blue dye solution to diffuse through the tablet and 
completely cover the surface. The wetting time was recorded as the simulated 
disintegration time. 
7.5.1.10. In-Vitro Dissolution Study:  (IP, 2007;USP 2007; Lachman L.,et al.,1991; 
Shankar Avulapati .et al , Yeole P.G., et al., 2006) 
The in vitro dissolution was carried out using USP type II dissolution 
apparatus was determined using USP Dissolution testing apparatus type-II (Paddle 
method; Veego Scientific VDA-8DR, Mumbai, India). 
Dissolution medium: pH 6.8 phosphate buffer for   30 minutes. 
Dose size: 25mg. 
Average weight of tablet: 200mg. 
Volume of medium: 900ml. 
Speed of paddle: 50 rpm. 
Temperature of dissolution medium: 37± 10 C. 
The tablets were placed in the dissolution medium and the apparatus was operated. At 
predetermined time intervals of 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours 5 ml aliquots 
were withdrawn and replacement was done each time with equal amounts of fresh 
dissolution medium maintained at same temperature. Each 5 ml aliquot was filtered 
through Whatman filter paper (No.41). 5 ml of sample was diluted to 10 ml pH 6.8 
phosphate buffer for 30 minutes and absorbance of these solutions was measured at 
206 nm using a Shimadzu-1700 UV spectrophotometer. Drug concentrations in the 
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C = K0t                                                                                                              
Log C = LogC0 – Kt / 2.303                                                                            
Qt = Kt1/2                                                                                                         
Mt / M∞ = Kt n                                                                                             
sample were determined from standard calibration curve. The release data were 
calculated by using PCP disso V3 software. 
7.6. KINETICS OF IN-VITRO DRUG RELEASE OF POROUS TABLETS                                                                    
( Brahmankar D.M. et al., 2009; Suvakanta Dash et al., 2010) 
To study the release kinetics of in-vitro drug release, data was applied to kinetic 
models such as Zero Order, First Order, Higuchi, Korsmeyer Peppas. 
Zero Order 
 
Where, ‘K0’ - zero-order rate constant expressed in units of concentration/time   
                    ‘t’ - time in hours 
First Order 
 
Where, ‘C0’ - initial concentration of drug 
                   ‘K’ - first order constant 
 ‘t’ - time in hours 
Higuchi 
 
Where, ‘Qt’ - amount of the release drug in time t 
                   ‘K’ - kinetic constant 
Korsmeyer Peppas 
 
Where, ‘Mt’ - represents amount of the released drug at time t 
                   ‘M∞’- overall amount of the drug (whole dose) released   
                   ‘K’ - diffusional characteristic of drug/ polymer system constant 
                ‘N’ - diffusional exponent that characterizes the mechanism of drug  release 
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7.7. STABILITY STUDY: (Janes T. Garnsten and Rhodes C.T., 2000; Manavalan R. 
and Ramasamy S., 2004) 
The test was performed according to the International Conference on 
Harmonization Guidelines titled “Stability Testing of New Drug Substances”. The  
Porous Tablets formulation were well packed in aluminium foils and stored at 40°C ± 
2°C at 75% RH ± 5% RH for accelerated temperature conditions for 3 months. The 
samples were withdrawn after periods of 1st month, 2nd month and 3rd month. The 
samples were analyzed for different characteristics to evaluate the changes occurred in 
the stability period. 
 
  
 RESULTS AND 
DISCUSSION 
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8.RESULTS AND DISCUSSION 
 
8.1. PREFORMULATION PARAMETERS 
8.1.1. physicochemical parameters of drug 
8.1.1.1. Organoleptic properties 
            Odourless, white or almost white crystalline powder. 
8.1.1.2. Melting point 
Melting point values of Losartan potassium sample was found to be in range 
of 1850C to 1890C. The reported melting point range for Losartan potassium was 
185.50C to 1860C. Hence, experimental values were in good agreement with official 
values. 
8.1.1.3. Solubility study 
Table 8.1: The solubility of Losartan potassium in various solvents 
Name of solvent Inference 
Distilled water Freely soluble 
Methanol Very soluble 
Iso propyl alcohol Soluble 
Acetonitrile  Sparingly soluble 
Acetone Slightly soluble 
Chloroform Slightly soluble 
0.1N HCl Slightly soluble 
Phosphate buffer(pH6.8) Soluble 
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8.1.2.  Analytical methods 
8.1.2.1.λmaxDetermination
 
The absorption maximum for Losartan potassium was found to be 206 nm. 
Figure 8.1: λ max observed for Losartan potassium in  pH 6.8 Phosphate buffer. 
8.1.2.2. Preparation of standard graph of Losartan potassium 
8.1.2.3. Preparation of standard graph of Losartan potassium in pH 6.8 
Phosphate buffer. 
UV absorption spectrum of Losartan potassium in pH 6.8 Phosphate buffer shows λ 
max at 206nm. Absorbances obtained for various concentrations of Losartanpotassium 
in pH 6.8 phosphate buffer are given in table no.8.2 and graph was graphically 
represented in figure 8.2. The graph of absorbance vs concentration for Losartan 
potassium was found to be linear in the concentration range of 2-16 µg /ml. The drug 
obeys Beer- Lambert’s law in the range of 2-16 µg /ml. 
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Table 8.2: Data of concentration and absorbance for  Losartan potassium in  pH 6.8 
phosphate buffer. 
S.No. Concentration (µg/ml) Absorbance 
1 0 0.000 
2 2 0.219 
3 4 0.435 
4 6 0.605 
5 8 0.812 
6 10 0.991 
7 12 1.183 
8 14 1.381 
9 16 1.574 
 
 
 
 
 
 
 
 
 
Figure 8.2: Standard graph of Losartan potassium in pH 6.8 Phosphate buffer. 
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Table 8.3:  Data for calibration curve parameters 
S. No. Parameters Values 
1 Slope (m) 0.0972 
2 Intercept(c) 0.0224 
3 Correlation coefficient (R) 0.9997 
 
8.1.2.3. Percentage purity of pure Drug 
            The percentage purity of drug was calculated by using calibration graph 
method (least square method) was shown in table 8.4. 
Table 8.4:  Percentage purity of pure drug 
  
The reported percentage purity for Losartan potassium is 98 to 102% (I.P. 1996). 
8.1.3. Compatibility testing of drug with polymer 
8.1.3.1. Fourier transforms Infra-Red (FTIR) spectroscopy 
FTIR study was carried out to check compatibility of drug with polymers. 
Infrared spectrum of Losartan potassium was determined on fourier transform infrared 
spectrophotometer using KBr dispersion method. The base line correction was done 
using dried potassium bromide. Then the spectrum of dried mixture of drug and 
potassium bromide was run followed by drug with various polymers by using Parkin 
elmer-Pharmaspec-1 FTIR spectrophotometer.All the FTIR spectrum were shown in 
figure 8.3-8.6. 
S. No. Percentage purity (%) Avg. percentage purity (%) 
1 100.02  
99.35 2 99.30 
3 99.40 
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 Figure 8.3: FTIR spectra of Losartan potassium 
 
Figure 8.4: FTIR spectra of Losartan potassium and Avicel 
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Figure 8.5: FTIR spectra of Losartan potassium and crosspovidone 
 
Figure 8.6: FTIR spectra of Losartan potassium and mannitol 
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Interpretation of FTIR Spectrum 
Table 8.5:Data for characteristic frequencies in FTIR spectrum of Losartan potassium 
Wave no.(cm-1) Inference 
2865.7 C-H stretching 
1465.63 C-H bending 
3621.66 O-H stretching 
1187.94 C-O stretching 
1353.78 O-H bending 
1257.36 C-H Methylene bending 
1068.37 Cl-Group 
1485.63 C-C m ring stretching 
 
Major functional groups present in Losartan potassium showed characteristic 
peaks in IR spectrum. Table 8.5 shows peaks observed at different wave numbers and 
their functional group associated with these peaks. The major peaks were identical to 
functional group of Losartan potassium. Hence, the sample was confirmed as 
Losartan potassium. 
 
8.1.3.2) Differential Scanning Calorimetry (DSC) 
           The compatibility and interactions between drugs and polymer were checked 
using differential scanning calorimetry (DSC) results obtained were shown in Figure 
8.7- 8.10 and Table 8.6 
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Figure 8.7: DSC thermal analysis of pure Losartan potassium 
 
Figure 8.8: DSC thermal analysis of Losartan potassium+ avicel 
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Figure 8.9: DSC thermal analysis of Losartan potassium + cross povidone 
 
Figure 8.10: DSC thermal analysis of Losartan potassium + mannitol 
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Table 8.6: Data for DSC thermogram parameters 
Sr. No. DSC thermogram sample Onset temperature(°C) Peak temperature(°C) 
1 Pure   Losartan   potassium 187.84 189.84 
2 Losartan   potassium  + avicel  
186.18 
 
188.67 
3 Losartan   potassium  + 
crosspovidone 
 
185.33 
 
182.94 
4 Losartan   potassium+ mannitol  
182.18 
 
187.67 
DSC thermogram showed that there was no interaction  found between drug and 
polymers. 
8.1.4. Characterization of powder blend 
The powder blends were prepared by mixing of various ingredients mentioned 
in table 8.7 and used for characterization of various flow properties of powder. 
                               Table 8.7: Flow properties of powder 
F 
Code 
 Bulk density 
(g/cm3)* 
Tapped  bulk 
density 
(g/cm3)* 
Hausner 
ratio (HR)* 
Carr’s index 
(IC)* 
Angle of repose 
(θ)* 
F1 0.555±0.000 0.666±0.000 1.200±0.00 16.66±0.00 30.212±0.58 
F2 0.566±0.015 0.700±0.048 1.235±0.05 18.95±0.23 28.697±0.01 
F3 0.588±0.000 0.734±0.048 1.248±0.08 19.59±0.51 28.522±0.00 
F4 0.546±0.029 0.652±0.019 1.195±0.05 16.20±0.78 29.557±0.61 
F5 0.545±0.013 0.638±0.019 1.171±0.03 12.88±0.06 29.561±0.45 
F6 0.476±0.000 0.600±0.017 1.219±0.02 20.64±0.25 30.988±0.42 
F7 0.546±0.029 0.652±0.019 1.195±0.05 16.20±0.82 28.682±0.64 
F8 0.545±0.013 0.625±0.000 1.146±0.02 12.72±0.16 25.412±0.59 
F9 0.526±0.000 0.600±0.017 1.140±0.03 12.30±0.49 30.730±0.21 
*All the values are expressed as mean± SD, n=3. 
TASTE MASKED  POROUS TABLETS OF LOSARTAN POTASSIUM                    RESULTS AND DISCUSSION 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR 100  
8.1.4.1. Bulk Density (BD) 
The powder blends bulk density ranged between 0.476±0.000 to 0.588±0.000 
gm/ml. 
8.1.4.2. Tapped bulk density (TBD)                                                                                                
 The powder blends  tapped bulk density range between 0.600±0.017 to 
0.734±0.048 g/ml. These values indicate good packing characteristics and the powder 
was not bulky. 
8.1.4.3. Carr’s Compressibility Index 
The carr’s index for all the formulations was found to be below 12% indicating 
that the powders have a excellent compressibility. 
8.1.4.4. Hausner’s Ratio 
The hausner ratio for all the formulations was found to be <1.25, indicating good 
flow properties. 
8.1.4.5. Angle of repose 
      The flow properties of granules were analyzed by determining angle of repose 
which was found to be between 25.412±0.59 to, indicating 30.730±0.21 excellent 
flow property. 
8.2. EVALUATION  OF  POROUS  TABLET 
8.2.1. Appearance 
The tablets were observed visually and did not show any defect such as 
capping, chipping and lamination. 
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8.2.2. Physical characteristic 
The physical characteristic of Losartan potassium porous tablets formulations 
(F1 to F9) such as thickness, diameter, hardness, friability, weight variation and drug 
content were determined and results of the formulations (F1 to F9) found to be within 
the limits specified in official books as per I.P. 
8.2.2.1. Dimension (Thickness and Diameter) 
Table 8.8: Physico-chemical characterization of Losartan potassium porous tablets: 
F Code Dimension Hardness 
(kg/cm2)* 
Friability 
(%)* 
Weight 
variation 
(%) 
Drug content 
(%w/w)* Diameter 
(mm)* 
Thickness 
(mm)* 
F1 8.0±0.0 3.00±0.00 2.10±0.000 0.590±0.02 1.448 100.80±0.2 
F2 8.0±0.0 3.00±0.00 2.10±0.020 0.632±0.25 1.139 99.47±0.4 
F3 8.0±0.0 3.00±0.00 2.16±0.012 0.697±0.12 1.799 100.72±0.1 
F4 8.0±0.0 3.00±0.00 2.09±0.008 0.805±0.18 1.162 100.03±0.8 
F5 8.0±0.0 3.00±0.00 2.13±0.026 0.668±0.13 1.123 99.55±0.95 
F6 8.0±0.0 3.00±0.00 2.12±0.008 0.688±0.23 1.755 100.14±0.9 
F7 8.0±0.0 3.00±0.00 2.10±0.004 0.486±0.12 1.440 100.5±0.68 
F8 8.0±0.0 3.00±0.00 2.08±0.004 0.667±0.07 1.406 99.37±0.5 
F9 8.0±0.0 3.00±0.00 2.10±0.000 0.454±0.07 0.655 98.59±0.7 
*All the values are expressed as mean± SD, n=3. 
Thickness and diameter specifications may be set on an individual product basis. 
Excessive variation in the tablet thickness and diameter can result in problems with 
packaging as well as consumer acceptance. The size (diameter)  of the tablets of all 
formulations were found to be 8.0±0.0 mm and thickness of all formulation was found 
to be 3.00. 
8.2.2.2. Tablet Hardness 
A difference in tablet hardness reflects difference in tablet density and 
porosity. The hardness of tablets was found to be in the range of 2.08±0.004 kg/cm2 to 
2.21±0.020 kg/cm2. This indicates good tablet strength. 
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8.2.2.3. Percent Friability 
Percentage friability of all the formulations was found between 0.454±0.07to 
0.697±0.12%. This indicated good handling property of the prepared porous  tablets. 
8.2.2.4. Weight Variation 
A tablet was designed to contain a specific amount of drug. When the average mass of 
the tablet is 200 mg the Pharmacopoeial limit for percentage deviation is ± 7.5 %. The 
percentage deviation from average tablet weight for all the tablet was found to be 
within the specified limits and hence all formulations complied with the test for 
weight variation according to the Pharmacopoeial specifications. 
8.2.2.5. Drug content of Losartan potassium 
           The content of active ingredients in the formulation was found to be between 
97.54±1.7 to 100.80±1.2 % w/w, which is within the specified limit as per IP 2007(i.e. 
90-110% w/w). 
8.2.5. In-vitro Disintegration time 
Table 8.9 In-Vitro Disintegration Time of All porous Formulations 
Formulations Code In-Vitro Disintegration Time* (Seconds) 
FT1 10.31 ± 0.121 
FT2 7.83 ± 0.528 
FT3 11.16 ± 0.115 
FT4 10.55 ± 0.128 
FT5 16.00 ± 0.000 
FT6 12.16 ± 0.708 
FT7 9.83 ± 0.994 
FT8 12.50 ± 0.135 
FT9 29.00 ± 0.464 
*All the values were expressed as a mean ± SD., n = 3 
The disintegration time of all the formulations were found to be within 30seconds, 
hence the porous tablets disintegration time has been greatly reduced due 
 
TASTE MASKED  POROUS TABLETS OF LOSARTAN POTASSIUM                    RESULTS AND DISCUSSION 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR 103  
to the pores  formed by sublimation. The disintegration time of porous tablets of 
formulation FT1-FT8 has reduced disintegration time compared to FT9. 
 8.2.6. Simulated Wetting Time: 
 
Figure: 8.11 Simulated Wetting Time of Porous tablet at different time intervals A. 0 
second, B. 5 seconds, C. 7 seconds D. 9 seconds 
Table 8.10 Simulated Wetting Time of All porous Formulations 
Formulations Code Simulated Wetting Time* (s) 
FT1 12.00 ± 0.000 
FT2 9.00 ± 0.000 
FT3 13.33 ± 0.527 
FT4 12.00 ± 0.000 
FT5 16.00 ± 0.000 
FT6 13.00 ± 0.000 
FT7 10.33 ± 0.577 
FT8 13.66 ± 0.577 
FT9 31.33 ± 0.154 
*All the values were expressed as a mean ± SD, n = 3.  
This test was indirect measurement to identify the disintegration time of the tablet in 
mouth. The simulated wetting time of porous tablets were reduced compared to 
nonporous tablets prepared by FT9.This indicates indirectly faster onset action of 
action of porous tablets. The variations in the disintegration time and stimulated 
wetting time were due to change in concentrations of excipients added in the tablets. 
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8.2.7.  In-Vitro Dissolution profile of porous tablets of Losartan potassium for 
formulation FT1-FT9 
 
 Table 8.11 In-vitro release profile of formulation FT1        
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 48.32 ± 0.77 7.02 24.16 0.50 
2. 3 69.72 ± 0.85 10.13 47.40 0.96 
3. 5 83.47 ± 1.09 12.13 59.08 1.46 
4. 10 95.53 ± 1.04 13.88 74.29 2.22 
5. 20 99.58 ± 0.09 14.47 85.93 2.74 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
Figure 8.12 In-vitro percentage release of formulation FT1 
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Table 8.12 In-vitro release profile of formulation FT2 
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 66.94 ± 1.29 9.73 33.47 0.50 
2. 3 91.50 ± 1.34 13.30 63.97 0.90 
3. 5 99.09 ± 0.63 14.40 76.50 1.14 
4. 10 - - - - 
5. 20 - - - - 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
Figure 8.13 In-vitro percentage release of formulation FT2 
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 Table 8.13 In-vitro release profile of formulation FT3    
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 49.99 ± 0.41 7.26 25.00 0.50 
2. 3 71.01 ± 0.34 10.32 48.67 0.94 
3. 5 83.18 ± 0.47 12.09 60.04 1.39 
4. 10 96.63 ± 0.68 14.04 74.98 2.24 
5. 20 99.56 ± 0.11 14.47 86.54 2.62 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
Figure 8.14 In-vitro percentage release of formulation FT3 
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Table 8.14 In-vitro release profile of formulation FT4 
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 52.48 ± 0.47 7.63 26.24 0.50 
2. 3 71.65 ± 0.35 10.41 50.13 0.90 
3. 5 85.54 ± 029 12.43 61.52 1.40 
4. 10 99.03 ± 0.36 14.39 76.90 2.23 
5. 20 99.65 ± 0.05 14.48 88.13 2.31 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
        Figure 8.15 In-vitro percentage release of formulation FT4 
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Table 8.15 In-vitro release profile of formulation FT5 
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 63.89 ± 1.43 9.28 31.95 0.50 
2. 3 88.88 ± 0.79 12.92 61.58 0.92 
3. 5 95.30 ± 0.77 13.85 73.79 1.13 
4. 10 99.44 ± 0.15 14.45 85.58 1.39 
5. 20 - - - - 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
        Figure 8.16 In-vitro percentage release of formulation FT5 
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Table 8.16 In-vitro release profile of  formulation FT6 
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 61.59 ± 0.52 8.95 30.80 0.50 
2. 3 87.25 ± 0.91 12.68 59.88 0.94 
3. 5 94.81 ± 0.17 13.78 72.34 1.19 
4. 10 99.46 ± 0.24 14.45 84.74 1.48 
5. 20 - - - - 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
        Figure 8.17 In-vitro percentage release of formulation FT6 
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Table 8.17 In-vitro release profile of formulation FT7 
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 51.59 ± 0.49 7.50 25.80 0.50 
2. 3 80.15 ± 0.16 11.65 52.51 1.03 
3. 5 83.85 ± 0.86 12.18 64.31 1.17 
4. 10 99.13 ± 0.17 14.40 77.90 2.14 
5. 20 99.53 ± 0.08 14.46 88.62 2.19 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
        Figure 8.18 In-vitro percentage release of  formulation FT7 
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Table 8.18 In-vitro release profile of formulation FT8 
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 51.31 ± 0.32 7.46 25.66 0.50 
2. 3 70.09 ± 0.31 10.18 49.02 0.90 
3. 5 82.79 ± 0.33 12.03 59.99 1.38 
4. 10 98.68 ± 0.29 14.34 75.36 2.36 
5. 20 99.76 ± 0.24 14.50 87.29 2.50 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
       Figure 8.19 In-vitro percentage release of formulation FT8 
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Table 8.19 In-vitro release profile of formulation FT9 
S. No. Time  (minutes) 
Percentage 
Drug Released 
(%)* 
Amount of 
Drug Released 
(mg) 
Dissolution 
Efficiency 
(%) 
Mean Dissolution 
Time (minutes) 
1. 1 50.79 ± 0.27 7.38 25.40 0.50 
2. 3 69.71 ± 0.28 10.13 48.64 0.91 
3. 5 82.53 ± 0.28 11.99 59.63 1.39 
4. 10 98.81 ± 0.28 14.36 75.15 2.39 
5. 20 99.52 ± 0.03 14.46 87.16 2.48 
6. 30 - - - - 
*All the values were expressed as a mean ± SD, n = 3 
 
        Figure 8.20 In-vitro percentage release of formulation FT9 
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            Figure 8.21: In-vitro percentage release of all formulations (FT1-FT9) 
 
 
        The drug release of formulation FT1,FT3,FT4,FT7,FT8 and FT9 were found to 
be above 99% at 20 minutes as the formulation contains average ratio of sublimation 
agents and the pores are formed superficially but in case of formulation FT2 good 
ratio of camphor was added as a perfect sublimation agent compared to all other 
sublimation agents which showed pores over the whole tablet influencing the release 
of the FT2.In formulation FT2 the pores formed highly influence the drug release as 
at the onset of 5 minutes the release was found to be above 99%. 
8.2.8. Kinetics of In-Vitro Drug Release: 
                The kinetics of in-vitro drug release was determined by applying the drug 
release data to various kinetic models such as Zero Order, First Order, Higuchi and 
Korsmeyer-Peppas. 
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8Figure 8.22 Best Fit Model (First Order) of Formulation FT1 
 
Figure 8.23 Best Fit Model (First Order) of Formulation FT2 
Figure 8.24 Best Fit Model (First Order) of Formulation FT3
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Figure 8.25 Best Fit Model (Korsmeyer Peppas) of Formulation FT4 
 
Figure 8.26 Best Fit Model (First Order) of Formulation FT5 
 
Figure 8.27 Best Fit Model (First Order) of Formulation FT6 
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Figure 8.28 Best Fit Model (Korsmeyer Peppas) of Formulation FT7 
 
Figure 8.29 Best Fit Model (First Order) of Formulation FT8 
 
            Figure 8.30 Best Fit Model (First Order) of Formulation FT9    
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 From the kinetic data given  it was observed that all prepared 
formulations except FT4 and FT7 were shown first order release, where as FT4 and 
FT7 were followed the Korsemeyer  peppas model. 
 It was also observed that highest correlation was found for first order log % 
drug remaining versus time (R2 > 0.99), which indicates the drug release dependent 
on the concentration of dissolved species. 
 The first order release also states that the drug dissolution in dosage forms 
such as those containing water-soluble drugs in porous matrices. So it was evident for 
the present prepared formulations.     
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8.3. STABILITY STUDY: 
Stability Study of porous Tablets: 
After exposure to accelerated stability conditions the formulation FT2 was 
analyzed for various evaluation parameters including general appearance at one 
month sampling interval. The results were depicted in Table 8.20 
Table 8.20 Stability Studies of porous Tablet Optimized Formulation FT2 
Characteristics Initial 1st Month 2nd Month 3rd Month 
Hardness   (kg/cm2) 
** 
2.10±0.020 2.10 ± 0.37 2.10 ± 0.25 2.09 ± 0.20 
Assay (% w/w)* 99.47±0.4 98.13 ± 0.12 98.06 ± 0.10 98.04 ± 0.10 
Disintegration Time 
(s)** 7.83 ± 0.52 
8.83 ± 0.04 8.83 ± 0.94 9.33 ± 0.75 
Simulated Wetting 
Time (s)* 9.00 ± 0.00 
10.66 ± 0.57 10.66 ± 0.57 11.33 ± 0.57 
Time 
(minutes) 
Percentage Drug Release of losartan potassium from porous 
tablets (%)* 
Initial 1st Month 2nd Month 3rd Month 
1 66.94 ± 0.29 65.93 ± 0.19 65.58 ± 0.10 65.39 ± 0.11 
3 91.50 ± 0.34 90.23 ± 0.08 89.93 ± 0.10 89.27 ± 0.56 
5 99.09 ± 0.63 98.38 ± 0.19 98.16 ± 0.11 97.93 ± 0.07 
*and **All the values were expressed as a mean ± SD, n = 3 and n = 6 respectively 
There were no characteristic changes observed in the color, surface (general 
appearance) at the end of three months when stability study was performed. 
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9.SUMMARY AND CONCLUSION 
 
Oral ingestion has long been the most convenient and commonly employed 
route of drug delivery due to its ease of administration, high patient compliance, least 
sterility constraints and flexibility in the design of the dosage form. Fast dissolving  
tablets has fast on set of action generally, in the present study sublimation technique 
was adopted as pores were formed in the tablets which reduces disintegration time. 
Losartan potassium has bitter taste and the taste was masked using sweetening agents.  
Losartan potassium plays a major role in treating hypertension. It acts as an 
angiotensin antagonist. It’s the drug with lower sideffects so used widely because of 
its high solubility, low dose and therapeutic use in  diseases, it was considered as an 
ideal drug candidate for the design of porous tablets.   
 A wide range of polymers was selected for formulating the tablets along with 
Sublimating agents to prepare the powder blend in 1:1 and 1:2 ratio with the active 
pharmaceutical agent, along with super disintegrants and sweetners. The tablets were 
prepared by direct compression and were subjected to sublimation.   
Porous tablets: 
The Porous tablet formulations were designed by using sublimating agents 
camphor, menthol, thymol, ammonium bicarbonate (FT1 to FT8), only super 
disintegrant  without sublimation agents(FT9). Other excipents a like Avicel, Talc, 
Magnesium stearate, Crosspovidone, Mannitol, Aspartame were added and flavouring 
agent added masks the bitter taste of the drug . 
For each designed formulation of porous tablets the powder blend of drug and 
excipients was prepared and evaluated for different micromeritic properties like Angle 
of Repose, Bulk Density, Tapped Bulk Density, Hausner’s Ratio and Carr’s  
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Compressibility Index in order to know the flow characteristics and all the 
results revealed that powder blend showed a good flow properties and thus also 
suitable for direct compression. The porous tablets were prepared by sublimation 
technique and the prepared porous tablets were evaluated for different evaluator 
parameters like Thickness, Weight variation, Hardness, Friability, Assay, Content 
Uniformity, In-Vitro Disintegration Time and Simulated Wetting Time. All the results 
obtained from the tests are correlated with the limits and were found to be within  the 
range. From the proposed study, the FT2 Porous tablet formulation was found to have 
least Disintegration Time and Simulated Wetting Time. 
                  The total drug release from FT2 formulation in pH 6.8  phosphate buffer 
(dissolution medium) was found to be within 15 minutes. While comparing with 
porous tablets  formulations with non-porous formulation, Porous tablets prepared by 
sublimation technique showed faster release. Stability Study at 40°C ± 2°C at 75% 
RH ± 5% RH for 3 months showed no significant changes. From the above 
parameters Formulation FT2 was concluded as the best formulation among all the 
prepared Porous tablet formulations and the bitter taste was masked by using 
sweetening agents. 
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10.FUTURE PROSPECTS 
 
 In this work physico-chemical characterization and in-vitro evaluation 
of Losartan potassium porous Tablets were performed. The following works has to be 
performed in future. 
1. The formulation step has to develop for the large scale production. 
2. Prediction of shelf life by conducting long term stability studies as per ICH 
guidelines. 
3. Evaluation of taste by in-vivo studies using human volunteers. 
4. In-vivo release studies are also essential for development of successful 
formulation. So, its need to perform the in-vivo release studies using different 
animal models. 
5. Establishment of correlation between the in-vitro and in-vivo studies. 
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